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Clostridium difficile is a significant pathogen causing a toxin-mediated enteric disease in
humans and animals. The incidence and severity of C. difficile associated disease (CDAD) in
humans have increased in the US with the emergence of hypervirulent strains and community
associated outbreaks. The detection of genotypically similar and identical C. difficile strains
implicated from human infections in foods and food animals suggest the potential role of food as
a source of community-associated C. difficile disease. C. difficile predominantly affects hospital
inpatients undergoing prolonged antibiotic therapy, which results in enteric dysbiosis, leading to
C. difficile spore germination, pathogen colonization in the intestine and subsequent toxin
production. Therapeutic agents that inhibit critical C. difficile virulence factors such as toxin
production, sporulation, and spore outgrowth without causing enteric dysbiosis could improve the
clinical outcome of C. difficile infections and prevent relapse of the infection. In this Ph. D.
research work, the efficacy of two plant-derived molecules, carvacrol (CR) and transcinnamaldehyde (TC), were investigated for reducing C. difficile toxin production. Gene
expression and cell culture studies were performed to elucidate the mechanisms behind the antitoxigenic mechanism of CR and TC. Moreover, the efficacy of CR on C. difficile sporulation,
germination, and spore outgrowth was also investigated. Furthermore, the effect of CR on CDAD
pathogenesis was investigated in a mouse model with special reference to its effect on themouse
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gut microbiome. The results revealed that sub-inhibitory concentrations (SIC) of CR and TC
reduced CD toxin production and cytotoxicity in vitro by downregulating toxin production genes
(p<0.5). In addition, CR inhibited C. difficile sporulation and spore outgrowth. Oral
supplementation of CR improved the clinical outcome in the C. difficile challenged mice, and
positively altered the gut microbiome composition (p<0.5). Furthermore, the potential food
transmission of C. difficile was investigated, where beef, pork and chicken samples obtained from
geographically distant grocery stores in Connecticut were tested for C. difficile. Presumptive C.
difficile isolates were characterized by ribotyping, antibiotic susceptibility, toxin production and
whole genome sequencing. The results revealed that C. difficile occurs at very low levels in raw
meat sold in Connecticut, but the isolates were resistant to multiple antibiotics.
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Chapter I
Introduction

1

Clostridium difficile is a Gram-positive, spore-forming, anaerobic bacterium that causes a
toxin-mediated enteric disease in humans (Weese, 2010). More than 300,000 cases of C. difficileassociated disease (CDAD) are reported annually in the United States, resulting in approximately
US$3 billion as healthcare costs (Ghose et al., 2007; Wilkins & Lyerly, 2003). According to a
study by the US Department of Health and Human Services, the New England region, including
Connecticut reported the highest rate of C. difficile associated hospitalizations in 2010 and 2011
(Steiner et al., 2012).The emergence of a hypervirulent strain, NAP1/ribotype 027 that produces
increased levels of toxins and a severe form of the disease in humans has been reported in the US
(Blossom & McDonald, 2007; Hookman & Barkin, 2009; Sunenshine & McDonald, 2006). C.
difficile predominantly affects long-term hospital inpatients and the elderly undergoing prolonged
antibiotic therapy (Hookman & Barkin, 2009). Prolonged antibiotic therapy results in the
disruption of the normal enteric microflora, leading to the germination of C. difficile spores and
pathogen colonization in the intestine with subsequent production of toxins (Dial et al., 2005). C.
difficile toxins, TcdA, and TcdB, act as glucosyl transferases that inactivate the Rho family
GTPases associated with F-actin regulation and consequently cause disruption of the cytoskeleton
and intestinal epithelial tight junctions (Keel & Songer, 2006; von Eichel-Streiber et al., 1999).
This leads to an inflammatory response with the release of cytokines and leukotrienes, causing
pseudomembrane formation in the intestine and watery diarrhea (Hookman & Barkin, 2009;
McDonald et al., 2006; Sunenshine & McDonald, 2006). The genes tcdA and tcdB, which encode
the toxins TcdA and TcdB, respectively, along with the genes encoding TcdR, an RNA polymerase
sigma factor required for maximal expression of tcdA and tcdB, TcdC, an antagonist of TcdR, and
TcdE, a holin-like protein needed for toxin excretion, collectively constitute the “pathogenicity
2

locus” in C. difficile (McDonald et al., 2006). Recent studies have suggested the possible
emergence of new virulent or antibiotic resistant C. difficile strains by horizontal gene transfer
between toxigenic and non-toxigenic strains (Brouwer et al., 2013). The Centers for Disease
Control and Prevention (CDC) recently listed C. difficile as one among the three urgent threats in
their report on emerging pathogens with antibiotic resistance (Steiner et al., 2012).
C. difficile disease has been traditionally regarded as a nosocomial infection in humans,
especially in those receiving prolonged antimicrobial therapy (Bartlett, 1997; Hookman & Barkin,
2009; McDonald et al., 2006). However, in recent years, an increase in the number and severity
of C. difficile infections in humans has been reported, particularly in those involving communities
outside the hospital environment and in low-risk subjects (McDonald et al., 2006; Rupnik et al.,
2009). Recent studies conducted by investigators worldwide have indicated the occurrence of C.
difficile in a variety of food animals. A rise in the isolation rates of the pathogen from animal
reservoirs is one potential reason attributed to the increased reports of human C. difficile infections
(Rupnik et al., 2009; Thitaram et al., 2011). In addition, C. difficile has been isolated from raw
and ready-to-eat meats at retail stores (Harvey et al., 2011a; Songer et al., 2009; Weese et al., 2009;
Weese et al., 2010). The detection of genotypically similar and identical C. difficile strains
implicated in human infections from foods and food animals (Rodriguez-Palacios et al., 2011;
Weese et al., 2011) further highlights the potential role of food as a source of communityassociated C. difficile disease (Marsh et al., 2011; Songer et al., 2009). Although a limited number
of studies in the U.S have investigated the prevalence of C. difficile on different meats, an in-depth
characterization of the meat isolates has not been performed. The prevalence of C. difficile on
foods observed in previous investigations varies from 0 to 40% (Harvey et al., 2011b; Limbago et
al., 2012; Songer et al., 2009; Weese et al., 2009).
3

Although exposure to broad-spectrum antibiotics predisposes patients to CDAD by
disrupting the normal gut flora (Bartlett, 1992; O'Connor et al., 2004), antibiotics are still the
primary line of treatment against C. difficile. In addition, the emergence of antibiotic resistance in
hypervirulent strains of C. difficile is increasingly reported worldwide, which further limits the
success of antibiotic treatment (Prabaker & Weinstein, 2011; Spigaglia et al., 2011). Since C.
difficile toxins are the major virulence factors responsible for the pathogenesis of CDAD,
identification of alternative therapeutic agents that inhibit C. difficile toxin production without
disrupting the normal gastrointestinal flora would potentially constitute a viable approach for
controlling CDAD.
Historically, plant compounds have been used for treating various diseases in traditional
medicine. Carvacrol (CR) is a monoterpenoid phenol present in oregano and thyme oils. Diverse
pharmacological actions of CR, including antimicrobial and anti-inflammatory properties, have
been previously demonstrated (Baser, 2008). Trans-cinnamaldehyde (TC) is an aromatic aldehyde
present as a major component of the bark extract of cinnamon. Both CR and TC are generally
recognized as safe chemicals for use in foods (GRAS) by the U.S. Food and Drug Administration
(FDA). Previous research conducted in our laboratory revealed that sub-inhibitory concentrations
(SICs; the concentrations that do not inhibit bacterial growth) of TC and CR increased the
sensitivity of multi-drug resistant Salmonella Typhimurium DT 104 to antibiotics by downregulating antibiotic resistance genes and the efflux pump, tolC (Johny et al., 2010). In addition,
our laboratory previously observed that TC inhibited biofilm synthesis and virulence in
uropathogenic Escherichia coli (Amalaradjou et al., 2010; Amalaradjou et al., 2011).
Based on published literature and preliminary research conducted in our laboratory, it is
hypothesized that meat is a potential source of multi-drug resistant C. difficile. Moreover, it was
4

hypothesized that CR and TC reduce C. difficile virulence by reducing toxin production and
sporulation without deleteriously affecting the normal enteric flora. The specific objectives of this
dissertation include
1. To determine the prevalence of C. difficile in retail meat sold in Connecticut, and to
characterize C. difficile meat isolates by phenotypic and genotypic tests.
2. To investigate the effect of CR and TC on C. difficile toxin production in vitro.
3. To investigate the effect of CR on C. difficile sporulation and spore germination in vitro.
4. To study the effect of CR on C. difficile pathogenicity in a mouse model.

5

Chapter II
Review of Literature

6

C. difficile is a gram-positive, spore-forming, anaerobic bacterium, which causes a toxinmediated enteric disease in humans (Hookman & Barkin, 2009). The symptoms of C. difficile
disease include abdominal pain, fever, fulminant colitis, toxic megacolon (bowel perforation),
sepsis and shock (Rupnik et al., 2009). In addition, asymptomatic colonization of C. difficile or
mild diarrhea has also been reported in some patients (Hensgens et al., 2012). C. difficile infection
has been associated with the use of and antibiotics, gastric acid suppressing agents and resultant
gut dysbiosis, which lead to the germination of spores in the stomach and selection for C. difficile
in the intestine (Bartlett, 1992; Dial et al., 2005; Kelly & LaMont, 1998).
Recent evidence indicates that C. difficile has emerged as a community-associated
pathogen (Beaugerie et al., 2003; Hensgens et al., 2012). C. difficile has been isolated from the
intestinal tract of many food animals, and several small-scale studies conducted in different parts
of the world have revealed the presence of C. difficile in retail meat and meat products (RodriguezPalacios et al., 2013a). These results raise concerns that foods could potentially be involved in the
transmission of C. difficile to humans.
1. Epidemiology of C. difficile infection:
The total annual number of cases of C. difficile infection in the U.S. is estimated to exceed
500,000 (Lessa et al., 2015), resulting in approximately US$3 billion annually as health care costs
(O'Brien et al., 2007). C. difficile infections have been reported by physicians as increasing in
severity and more difficult to treat than in the past (Hookman & Barkin, 2007; Sunenshine &
McDonald, 2006). Among patients diagnosed with C. difficile infection, relapse or re-infection
occurs in 12% to 24% within 2 months (Sunenshine & McDonald, 2006) Moreover, the mortality
of the disease associated with C. difficile in the U.S. have increased from 5.7 per million to 23.7
per million from 1999 to 2004 (Redelings et al., 2007), and the incidence rate among hospitalized
7

patients doubled from 2001 to 2010 (Reveles et al., 2014).
Traditionally, C. difficile was considered a nosocomial pathogen that mainly affected the
elderly, the severely ill, and long-term hospital inpatients (Hookman & Barkin, 2007; Hookman
& Barkin, 2009). However, recently some changes in the epidemiology of C. difficile have been
reported. For example, an increase in community-acquired C. difficile associated disease (CDAD)
has been reported, especially in populations that were previously considered at low risk of the
infection (Beaugerie et al., 2003; Lessa, 2013; Rupnik et al., 2009). In a case-control study on
community acquired C. difficile infections, only half of the cases included in the study had received
antibiotic therapy within four weeks of infection, and one-third had not been exposed to antibiotics
or recently hospitalized (Wilcox et al., 2008). Another change in the epidemiology of C. difficile
is that an increase in the morbidity, mortality and relapse rate in infections has been reported in
the United States and elsewhere, which is attributed to the emergence and dissemination of a new
hypervirulent strain, classified as North American Pulsotype 1(NAP 1) by pulsed field gel
electrophoresis (Arroyo et al., 2005; Rupnik et al., 2009). This strain belongs to the toxin type III
and ribotype 027 (Loo et al., 2005). Emerging antimicrobial resistance in C. difficile has also been
reported by many investigators, especially resistance to fluoroquinolones (Drudy et al., 2007;
McDonald et al., 2005; McDonald, 2005; Sebaihia et al., 2006), clindamycin and erythromycin
(Qiong & Haihui, 2015), metronidazole (Musher et al., 2005; Pepin et al., 2005) and vancomycin
(Kelly & LaMont, 2008). Moreover, a high-level resistance to gatifloxacin and moxifloxacin was
reported in the NAP1/R 027 isolates (Kelly & LaMont, 2008; McDonald et al., 2005). In light of
this, the CDC has listed C. difficile as one of the three urgent threats in their recent report on
emerging pathogens with antibiotic resistance (Steiner et al., 2012)

8

2. C. difficile infection and pathogenesis
2.1. C. difficile associated disease (CDAD) in humans
C. difficile associated disease (CDAD) manifests as mild, moderate or severe disease in
humans (Hookman & Barkin, 2009). The mild form of the disease is usually asymptomatic or
manifested with mild fever and abdominal pain. Watery diarrhea is the principal symptom of
moderate and severe CDAD in affected patients (Kelly & LaMont, 1998). In addition to watery
and rarely bloody diarrhea, abdominal distension and leukocytosis are also seen in severe disease,
which leads to complications and potentially death (Hookman & Barkin, 2009; Kelly & LaMont,
1998; Knight & Surawicz, 2013). Patients with severe CDAD may lose serum protein in stool
leading to hypoalbuminemia, which inturn results in edema and occasional ascites (Dansinger et
al., 1996; Rybolt et al., 1989). High fever, leukocytosis, and detectable toxins in the stool are are
of significant diagnostic value in clinical CDAD (Knight & Surawicz, 2013). Occasionally,
patients suffer from abdominal pain caused by colonic distention and toxic megacolon. In addition,
marked leukocytosis (> 50,000/μL) and lactic acidosis are indications of a serious clinical
condition, which warrants surgical or advanced medical intervention (Knight & Surawicz, 2013).
2.2 Pseudomembranous Colitis
The classical sign of complicated CDAD is pseudomembraneous colitis (Hookman &
Barkin, 2009). Occasionally, other complications such as colonic perforation and sepsis may
follow pseudomembranous colitis (Kelly & LaMont, 1998; Knight & Surawicz, 2013; Rupnik et
al., 2009). Pseudomembraneous colitis could be visualized using lower endoscopy as yellow
membranous plaques in the colonic lumen formed by necrotic epithelial debris, inflammatory cells,
and proteinaceous exudates (Hookman & Barkin, 2009). In advanced stages, pseudomembranous
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colitis leads to sepsis and death in some patients, especially in the elderly patients (Knight &
Surawicz, 2013).
2.3. Pathogenesis C. difficile associated disease (CDAD)
The mode of transmission of C. difficile infection in humans is primarily via the fecal-oral
route (Hookman & Barkin, 2009). C. difficile spores are extremely resistant to physical and
chemical agents, and can survive in the environment such as hospital surfaces and equipment for
long periods (Bettin et al., 1994; Jabbar et al., 2010; Siani et al., 2011). Ingested C. difficile spores
can survive the acidity of the stomach and reach the intestine, where, especially in the absence of
normal gut microflora, spores germinate to vegetative cells in presence of a germinant, mainly
taurocholic acid (Kelly & LaMont, 1998; Knight & Surawicz, 2013). Bile salts including
taurocholic acid are actively secreted into the small intestine from the gall bladder, and most of
the secreted bile salts are reabsorbed in the distal ileum. The residual bile salts remaining in the
distal part of the intestine are readily converted to secondary bile salt metabolites by normal benign
gut flora, which in turn minimize the availability of taurocholic acid for C. difficile spore
germination (Kelly & LaMont, 1998; Knight & Surawicz, 2013). Therefore disruption of normal
gut flora makes tautocholic acid available for C. difficile spore germination in presence of other
co-germinants such as glycine. The disruption of normal gut flora is predominantly associated with
long-term antibiotic therapy, and um-metabolized taurocholic acid serves as a potent germinant
for C. difficile spores in clinical cases (McFarland, 2008; Wheeldon et al., 2011). The vegetative
cells of the bacterium multiply in the intestinal crypts, producing toxin A and B, the major
virulence factors of C. difficile (Kuehne et al., 2011).
C. difficile toxins inactivate Rho GTPases in colonic epithelial cells by glycosylation (Deng
& Barbieri, 2008; Kuehne et al., 2011). Rho GTPases are critical in cell to cell adhesion,
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cytokinesis, secretion, and most importantly in the maintenance of the cytoskeleton. The
inactivation of GTPases by toxin A and B leads to the disruption of F-actin regulation, which in
turn results in the disruption of the cytoskeleton and the intestinal epithelial cell tight junctions
(Jafari et al., 2010; Rupnik et al., 2009). The disruption of epithelial tight junctions and increased
epithelial permeability subsequently result in severe diarrhea. In addition, toxin A causes cell
rounding, detachment, apoptosis, and induce the secretion of proinflammatory cytokines,
including IL-8, a strong chemoattractant for neutrophils (El Feghaly et al., 2015; Monaghan, 2015;
Solomon, 2013). Further, neutrophils cause severe tissue damage due to the release of lytic
enzymes and free radicals. Moreover, toxin A interacts with macrophages in the lamina propria
and causes further release of cytokines such as IL-12, IL-18, interferon gamma, IL-1β, tumor
necrosis factor alpha and other proinflammatory proteins (El Feghaly et al., 2015; Monaghan,
2015; Solomon, 2013). Altogether, necrotic epithelial debris admixed with inflammatory cells and
exudates form a pseudomembrane over the colonic luminal surface which is presented as a
classical pseudomembranous colitis (Hookman & Barkin, 2009). In adverse conditions, exuberant
inflammatory reactions and release of systemically active cytokines, complicated by fluid loss
resulting from diarrhea may culminate in systemic shock and death (Knight & Surawicz, 2013).
2.4 C. difficile toxins
Similar to several other bacterial exotoxins, C. difficile toxins are high molecular weight
proteins (Popoff & Bouvet, 2009; Voth & Ballard, 2005). C. difficile toxin A (TcdA, enterotoxin)
and toxin B (TcdB, cytotoxin) which are responsible CDAD in humans represent the major
virulence factors of the pathogen (Kelly & LaMont, 1998; Stanley et al., 2013). These toxins are
members of a family of large clostridial toxins (LCTs), produced by pathogenic Clostridia such as
C. sordellii, C. novyi, C. perfringens (Davies et al., 2011; Popoff & Bouvet, 2009). In addition,
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binary toxins (CdtA and CdtB) are produced from various hypervirulent C. difficile strains can
also contribute to the severity of CDAD in affected patients. (Bacci et al., 2011; Barth & Stiles,
2008; Gerding et al., 2014).
C. difficile toxins, TcdA and TcdB are 308 and 270 kDa proteins, respectively, with 49%
identity and 63% similarity in their amino acid sequence (Davies et al., 2011). Both TcdA and
TcdB are homologous AB toxins; A subunit with catalytic activity and B subunit associated with
the delivery of A subunit into host cells (Davies et al., 2011; Popoff & Bouvet, 2009). The A
subunit is structurally an N-terminal glucosyltransferase (GTD) domain that inactivates Rho
family GTPases in the host cell (Voth & Ballard, 2005). Three additional domains present in the
B subunit associated with the delivery of GTD into the target cell include receptor-binding domain,
pore-forming domain, and autoprotease domain. These combined AB domains in C. difficile toxins
act in four steps 1) binding and internalization, 2) pore-formation and translocation of the GTD,
3) autoproteolysis and release of the GTD 4) inactivation of host GTPases by glycosylation (Pruitt
& Lacy, 2012).
Both TcdA and TcdB induce rounding of affected cells (Pruitt & Lacy, 2012). Despite a
comparable structure and mechanism of action, TcdA and TcdB have differences in their
phenotypic characteristics. It has been demonstrated that TcdB is 100–10,000 times more potent
than TcdA in its cytopathic effect in various cell types (Voth & Ballard, 2005). In addition to the
cell rounding, TcdA and TcdB can cause cells death (cytotoxic effect) through apoptosis and
necrosis (Chumbler et al., 2012; Kuehne et al., 2011). Earlier studies suggested TcdA as a key
virulence factor in CDAD, where it causes initial damage in the enterocytes, which facilitate the
entry and further damage by TcdB (Gerhard et al., 2008; Kuehne et al., 2011; Sutton et al., 2008).
However, recent studies demonstrated TcdB as the major virulence factor in CDAD, and TcdA is
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not essential for CDAD pathogenesis in humans (Lyras et al., 2009; McDonald et al., 2005).
Moreover, TcdA−TcdB+ strains of C. difficile cause the similar degree of damage as
TcdA+TcdB+ strains in humans, and no pathogenic TcdA+TcdB− strains have been detected in
humans (Sambol et al., 2000).
Similar to TcdA and TcdB, the binary toxins also act as ADP-specific ribosyltransferase,
which also disrupt actin (Barth & Stiles, 2008; Gerding et al., 2014). The binary toxins augment
the adherence of C. difficile to the target cells and contribute to virulence in C. difficile infections
in humans (Gerding et al., 2014; Hemmasi et al., 2015; Schwan et al., 2009). Interestingly, it was
observed that TcdA−TcdB-, binary toxin-producing strains of C. difficle can cause enterocyte
damage, indicating the significance of binary toxins in CDAD pathogenesis (Gerding et al., 2014).
2.5. Regulation of C. difficile toxin production
C. difficile toxins TcdA and TcdB are encoded by tcdA and tcdB, respectively located in a
single operon, and expressed during the late log phase and early stationary phases of bacterial
growth (Voth & Ballard, 2005). TcdA and TcdB, associated regulatory proteins TcdR and TcdC
along with holin-like protein, TcdE are encoded in a 19.6 kb genomic region known as the
Pathogenesity locus (Paloc) of the C. difficile genome (Dingle et al., 2013; Neyrolles et al., 2011).
TcdR, the positive regulator of C. difficile toxin production, is functionally an alternative sigma
factor that promotes TcdA and TcdB transcription (Bouvet & Popoff, 2008; Dupuy &
Matamouros, 2006). TcdC is a negative regulator of toxin production within the Paloc region,
which inhibits TcdR-dependent toxin gene transcription binding to TcdR complex (Dupuy et al.,
2008; Matamouros et al., 2007). In addition, TcdE, a porin protein helps in the delivery of C.
difficile toxins to the exterior of the bacterial cell (Govind & Dupuy, 2012; Govind et al., 2015).
In addition to the regulatory genes located in the Paloc region, C. difficile toxin production
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is regulated by genes located outside the pathogenicity locus, such as codY and ccpA (Antunes et
al., 2011a; Dineen et al., 2010). The CodY is a global regulator encoded outside of the PaLoc
region, which functions as a strong repressor of toxin production (Dineen et al., 2007). CodY is a
global repressor of virulence associated genes in various Gram-positive bacteria, including
clostridia (Dineen et al., 2007; Fisher et al., 1996; Guedon et al., 2001; Lobel et al., 2012). In C.
difficile, CodY is expressed in response to branched chain amino acids, binds to the tcdR promoter
region, which in turn suppresses toxin production (Dineen et al., 2007).
In addition to CodY, another important regulatory system for C. difficile toxin production
is CcpA mediated repression (Antunes et al., 2011b). CcpA, a member of the LacI/GalR family of
transcriptional regulators, takes part in carbon catabolite repression in low G+C Gram-positive
bacteria (Antunes et al., 2011b; Antunes et al., 2012; Li et al., 2015). Carbon catabolite repression
system recognizes rapidly metabolizable carbon sources such as glucose in the medium and acts
upon several genes responsible for nitrogen and carbon metabolism (Antunes et al., 2011b).
Moreover, in several pathogenic Gram-positive bacteria such as Clostridium and Bacillus, CcpA
regulates virulence-associated genes (Jiang et al., 2015; Li et al., 2015). Similarly, in C. difficile,
CcpA recognizes glucose and other carbon sources in the media and suppresses the toxin
production, sensing a nutritious environment (Antunes et al., 2011b). In addition, it has been
demonstrated that sporulation gene, spo0A regulates both sporulation and toxin production in C.
difficile (Pettit et al., 2014). However, the mechanism is yet to be delineated.
3. C. difficile sporulation
3.1 C. difficile spores
Sporulation is a critical virulence factor in C. difficile pathogenesis. C. difficile spores being
survival structures that can withstand unfavorable physical, chemical and metabolic conditions,
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play an important role in C. difficile persistence in the environment, transmission to new
susceptible individuals and relapse in temporarily recovered patients (Paredes-Sabja et al., 2014c).
Sporulation in C. difficile is a complex and less understood process. Vegetative cells of C. difficile
readily sporulate during egestion, contaminate the environment and initiate a new infectious cycle
through feco-oral route. In laboratory conditions, C. difficile sporulates in early stationary phase
or death phase; however, the cues that initiate C. difficile sporulation are not fully identified.
Various environmental stimuli such as scarcity of nutrients, physical and chemical stress factors,
oxidative stress (aerobic environment) and quorum sensing are considered as initiators of C.
difficile sporulation (Higgins & Dworkin, 2012; Paredes-Sabja et al., 2014c).
Sporulation process in C. difficile involves an asymmetric division of sporulating
vegetative cells to a forespore and a mother spore. The formation of and the interaction between
these two compartments yield highly resistant and metabolically dormant survival structures
(Burns & Minton, 2011; Edwards & McBride, 2014; Talukdar et al., 2014). The larger mother
spore engulfs the smaller forespore, which eventually becomes the functional spore. C. difficile
spores are composed of seven distinct layers or compartments. The innermost compartment is the
spore core, which carries the genetic elements and essential proteins, including enzymes (ParedesSabja et al., 2014c). Low water content and high dipicolinic acid concentration in the spore core
are predominantly responsible for spore resistance reported in C. difficile (Setlow, 2007).
Enveloping the spore core is the inner membrane, which is mainly composed of phospholipids
(Cowan et al., 2004). The inner membrane is surrounded by germ cell wall, which is further
protected by a thick peptidoglycan layer, which in turn is covered by an outer membrane formed
from the mother cell. The entire structure is further surrounded by a proteinaceous spore coat,
which provides resistance to most disinfectants.
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3.2 Regulation of C. difficile sporulation
The sporulation process in C. difficile is regulated by the master regulator spoOA. (Saujet
et al., 2014). Loss of function mutation of spoOA has been shown to considerably impair the
transmission of C. difficile infection in mice (Deakin et al., 2012a). Phosphorylation of Spo0A is
an essential step in the initiation of the sporulation process, where several histidine kinases,
including s CD1352, CD1492, CD1579, CD1949, and CD2492, encoded by cody play a vital role.
C. difficile orphan histidine kinase CD1579 autophosphorylate and transfer a phosphate group to
Spo0A (Underwood et al., 2009). However, the role of other histidine kinases is yet to be known.
The regulation of sporulation in C. difficile is a complex process chiefly controlled by the RNA
polymerase sigma factors (σF, σE, σG, and σK). Sigma factors σF and σG are associated with
forespores, and σE and σK are associated with the mother cell (Fimlaid et al., 2013). The forespore
protein SpoIIR is needed for σE activation (Saujet et al., 2014), which is dependent on SpoOA, the
master regulator. spoIIID encodes for a regulator in the mother cell. The sigma factors σE and σG
and spoIIID are critical for σK production and activation (Paredes-Sabja et al., 2014a). In addition,
SpoIVA is essential for the synthesis of spore coat surrounding the forespore (Putnam et al., 2013).
3.3 C. difficile spore germination
Patients contract C. difficile infection by ingestion of spores. Germination of spores in the
small intestine to form vegetative cells is an important step in initiating CDAD (Paredes-Sabja et
al., 2014b). Generally, germination of Clostridial spores is induced by specific germinant receptors
that sense distinctive small molecules, which are highly species specific. Activation of these
receptors induce the release of monovalent cations such as H+, Na+, and K+ and dipicolinc acid
chelated to calcium (Ca-DPA) stored in the spore core (Paredes-Sabja et al., 2011). Release CaDPA activates cortex hydrolases that degrade the peptidoglycan layer in the cortex, subsequently
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leading to hydration of the spore core and reactivation of the spore core metabolism (ParedesSabja et al., 2011). In closely related species like C. perfringens, induction of the cortex hydrolase
protein SleC, depends on its cleavage by another family of proteases, including CspA, CspB, and
CspC (Labbe et al., 1978; Paredes-Sabja et al., 2011). In C. difficile also, CspC is established as a
spore germinant receptor (Burns et al., 2010; Francis et al., 2013; Paredes-Sabja et al., 2014b). C.
difficile spore germination is induced by specific bile salts, cholate and its derivatives
(glycocholate, taurocholate, cholate and deoxycholate) in the presence of a cogerminant L-glycine.
However, germination of C. difficile spores in the absence of these small molecules has been
observed in experimental settings, suggesting that other complex pathways are involved in this
process (Francis et al., 2013; Giel et al., 2010; Sorg & Sonenshein, 2008). It is demonstrated that
CspC triggers Ca-DPA release from the spore core upon activation by taurocholate, however, the
exact mechanism is not clear. In C. difficile, the serine protease, CspB is required for the
conversion of pro-SleC into mature SleC resulting in cortex hydrolysis and spore germination
(Francis et al., 2013; Paredes-Sabja et al., 2014b).
4. C. difficile and gut microbiome
A healthy and normal gut microflora is crucial for preventing pathogen colonization,
including C. difficile (Britton & Young, 2014). Therefore, the most important predisposing factor
for C. difficile infection is the disruption of normal gut microbiota (Hookman & Barkin, 2009).
Antibiotic therapy significantly alters the microbial diversity; and in many case changes in the
microbial diversity persist even after withdrawing the antibiotic (Antonopoulos et al., 2009;
Dethlefsen et al., 2008b). The major antibiotic or antimicrobial classes that are documented to
predispose C. difficile infection include fluoroquinolones clindamycin, cephalosporins, and
penicillins (Blossom & McDonald, 2007; McFarland, 2008).
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Throughout life, the human gut microbiota undergoes continuous shifts and alterations
(Hopkins et al., 2001a). The gut microbiome of a healthy adult is almost stable; however, the
microbial composition undergoes significant alterations and becomes less diverse as age advances
(Biagi et al., 2010; Claesson et al., 2011; Hopkins et al., 2001a). In elderly people, protective
populations such as Bifidobacterium and other members of Firmicutes considerably diminish
accompanied by an increase in undesirable species of Proteobacteria in the gut (Biagi et al., 2010;
Claesson et al., 2011; Hopkins et al., 2001b). Moreover, age-related senescence in the immune
status of the elderly, along with frequent hospital visits during old age contribute to a detrimental
alteration in the gut microbiome and subsequent colonization of C. difficile (Seekatz & Young,
2014).
Other important factors that detrimentally affect gut microbiota and predispose C. difficile
infection are the use of proton pump inhibitors and chronic gastrointestinal diseases (Berg et al.,
2013; Dial et al., 2005; Vesper et al., 2009). Proton pump inhibitors alter the pH of the gut, thereby
affecting microbial populations, especially beneficial bacteria such as Lactobacillus species
(Altman et al., 2008; Vesper et al., 2009). In addition, conditions such as inflammatory bowel
disease induce significant gut dysbiosis, reducing the diversity of Firmicutes and Bacteroides
population, accompanied by an increased Proteobacteria in the gut of affected patients (Manichanh
et al., 2006; Nagalingam & Lynch, 2012).
The Firmicutes to Bacteroides ratio in gut increases as age advances and an elevated ratio
is an indication of gut dysbiosis in humans (Ling et al., 2014; Mariat et al., 2009). Similarly, in C.
difficile infected patients, a significant increase in Firmicutes to Bacteroides ratio is observed (Ling
et al., 2014). Moreover, a decrease in Firmicutes, especially the depletion of Ruminococcaceae,
Lachnospiraceae, and butyrogenic bacteria within this phylum has been found to be associated
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with C. difficile infection and nosocomial diarrhea in humans (Antharam et al., 2013). In addition,
C. difficile infected patients were reported to possess a higher gut count of Enterobacteriaceae
(Proteobacteria) and decreased Enterococcaceae (Firmicutes) (Hopkins & Macfarlane, 2002; Rea
et al., 2012; Schubert et al., 2014).
Interestingly, a majority of infants are colonized with C. difficile, however; they do not
develop the disease (Rousseau et al., 2011). It is found that a comparatively higher population of
Bifidobacteria in the gut exerts a protective effect against C. difficile in infants (Rousseau et al.,
2011). Moreover, healthy young individuals have a higher population of Bifidobacteria and more
diverse Bacteroides compared with elderly people (Rea et al., 2012). Altogether C. difficile
infected patients possess a less diverse gut microbiota compared to non-infected healthy adults
(Rea et al., 2012).
5. Treatment strategies of C. difficile infection in humans
Medical management of C. difficile infection is still one of the most problematic
therapeutic challenges in hospital settings. The treatment of C. difficile infection is often
complicated by relapse of infection that ranges from 20% after the first episode to 60% after
multiple events of recurrence. The treatment strategies against CDAD is multifactorial and involve
diverse approaches to address bacterial colonization of the gut, toxin-mediated colonic
inflammation, fluid loss due to diarrhea, disruption of the gut microbiome, and transmission and
relapse of infection due to C. difficile spores.
5.1 Antibiotic therapy
Antibiotic treatment against CDAD is chosen based on the severity and recurrence rate of
the infection. Metronidazole or vancomycin treatment for 10 to 14 days has been found to be
effective in 50% of the patients after the first episode of a recurrent C. difficile infection (Longo et
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al., 2015). Subsequent episodes of recurrent C. difficile infections are difficult to treat due to the
persistence of spores in the gut and an inadequate immunologic response against C. difficile toxins.
Recurrent C. difficile infection is usually managed with a decreasing or pulsed regimen of
vancomycin. A pulsed regimen of vancomycin is reported to be more effective against recurrent
CDI compared to conventional dosing (McFarland et al., 2002). A recently developed antibiotic,
namely fidaxomicin has been found to be more efficacious in treating CDAD after the second and
subsequent episodes of CDAD (Zhanel et al., 2015). Moreover, fidaxomicin was found to be more
effective than vancomycin in preventing relapse and re-infection in affected patients (Housman et
al., 2015; Zhanel et al., 2015). Fidaxomicin was also shown to reduce C. difficile toxin production
and sporulation in vitro, suggesting an improved clinical outcome and reduced incidentce of
relapse in treated patients (Allen et al., 2013; Babakhani et al., 2013; Babakhani et al., 2012). Other
anti-C. difficile antibiotics include rifaximin, nitazoxanide, teicoplanin, ramoplanin, and
tigecycline; however, their therapeutic use is limited in practical settings due to a lack of adequate
clinical data, antibiotic resistance potential, higher cost of treatment.
The efficacy of antibiotics, including fidaxomicin is limited in patients suffering from
severe colitis associated with advanced C. difficile infection. In such cases, emergency colectomy
or a diverting ileostomy with a colonic lavage with vancomycin is usually performed. Moreover,
C. difficile has been reported to acquire resistance against most of the currently used antibiotics
(Blossom & McDonald, 2007; Prabaker & Weinstein, 2011; Qiong & Haihui, 2015; Spigaglia et
al., 2011; Spigaglia et al., 2008; Steiner et al., 2012), thereby warranting alternate and effective
therapeutic strategies that can control the pathogen.
5.2 Fecal microbial transplantation
The colonic microflora provides colonization resistance against most of the microbial
20

pathogens, and its disruption due to antibiotic therapy is the major predisposing factor of CDAD.
Oral antibiotic therapy results in a rapid decline in colonic microbial diversity and this change can
last several weeks to months. Terminating the antibiotic regimen is critical in eliminating C.
difficile from the intestine and initiating the recovery of microbial composition and diversity
(Ofosu, 2016a). However, a complete replenishment of the colonic microbiome may take several
weeks, and the relapse of C. difficile infection can occur within this period (Dethlefsen et al.,
2008a; Jernberg et al., 2007). Fecal microbial transplantation has recently been introduced as a
safe and effective treatment against recurrent C. difficile infection. Fecal microbial transplantation
is documented to prevent relapse of CDAD in patients with a history of recurrent infection (van
Nood et al., 2013). This procedure involves screening of healthy donors, the collection of fecal
material that contains important bacteria particularly from the Bacteroidetes and Firmicutes phyla,
and introducing the fecal material to the colon of the recipient orally or rectally (Ofosu, 2016b;
Shahinas et al., 2012).

This method was first recorded in 1958 and recently emerged as an

effective strategy against CDAD with more than 90% success rate (EISEMAN et al., 1958;
Kassam et al., 2013). Fecal transplantation along with parallel anti – C. difficile antibiotic therapy
was also found to be more efficacious than administering antibiotics alone (van Nood et al., 2013).
However, the exact mechanism of how fecal microbial transplantation prevents recurrent CDAD
is not known. In addition, the ideal composition of specific bacterial taxa and their significance in
conferring optimum colonization resistance against C. difficile in the colon is also unknown.
Moreover, screening of healthy donors and ruling out the possibility of transmission of other
infectious disease through transplanted fecal material are critical steps in this method (Ofosu,
2016b; Pacheco & Johnson, 2013). Fecal transplantation is still not considered as a primary line
of treatment against CDAD, and further investigations on this approach are currently underway
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(Ofosu, 2016a). The efficacy of administering capsules containing the spores of fecal microbial
flora compared to the conventional fecal transplantation is also being investigated.
5.3 Vaccination
Animals immunized with toxoids prepared from TcdA and TcdB have been reported to
possess resistance against C. difficile infection. Results revealed that specific anti-toxin serum IgG
can successfully prevent toxin-mediated colitis in animals, suggesting its potential as a vaccination
strategy against human CDAD (Ghose et al., 2007; Siddiqui et al., 2012). In addition, passive
immunization with monoclonal anti-toxin immunoglobulin was found effective in animal models
(Zhao et al., 2014). However, the cost effectiveness is a major concern in primary infections
(Ofosu, 2016a; Solomon, 2013). The toxoid A and B parenteral vaccines have been found safe and
relatively effective in human subjects (Kotloff et al., 2001). However, it should be noted that
vaccination fails to prevent C. difficile colonization in gut, but it can only ameliorate the severity
of infection by blocking toxin-mediated pathology (Longo et al., 2015).
5.4 Probiotics
Probiotics are live microorganism that when administered in adequate amounts confer a
health benefit on the host (Sanders, 2008). Probiotics are widely considered to exert preventive
and prophylactic potential against CDAD and its recurrence. Several theories have been postulated
to explain the protective effect of probiotics against various enteric diseases, including CDAD.
The protective effect of probiotics is primarily attributed to their role in inhibiting or modulating
pro or anti-inflammatory signaling pathways in the gut (Kumari et al., 2011; Patel & Lin, 2010).
However, in the case of CDAD, probiotics are prescribed as an adjunct therapy with antibiotics to
maintain gut microflora, which is eliminated or disrupted during antibiotic treatment. Many
clinical trials with probiotic bacteria such as Saccharomyces boulardii, Lactobacillus casei and L.
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acidophilus have demonstrated their beneficial effect against recurrent CDAD (Johnson et al.,
2012).
Various studies have reported beneficial effects of S. boulardii in preventing CDAD
incidence in patients undergoing antibiotic therapy (Surawicz et al., 2000). Moreover, probiotic
administration significantly reduced the recurrence of CDAD in infected patients. (Crow et al.,
2015). In a controlled trial, the patients undergoing antibiotic therapy were provided with a cocktail
of Lactobacillus casei, Lactobacillus bulgaricus and Streptococcus thermophilus or a placebo
drink, and the incidence of CDAD was recorded in treatment groups. No CDAD was reported in
probiotic cocktail group as opposed to 17% incidence in the placebo group (Hickson et al., 2007).
Lactobacillus plantarum 299v administration has also been reported to prevent CDAD in
hospitalized patients undergoing antibiotic therapy (Kujawa-Szewieczek et al., 2015). Although
several studies are suggesting the beneficial effects of probiotic bacteria in preventing CDAD and
its recurrence in patients, the use of probiotics is limited to a prophylactic approach, and further
studies are required to confirm their effectiveness for treating CDAD.
5.5 Alternative therapeutic strategies against CDAD
All therapeutic strategies currently available to prevent CDAD have their limitations, and
C. difficile is still considered as one of the most ‘difficult to tackle’ nosocomial pathogens, thereby
triggering an intensive search for alternative approaches to prevent CDAD. Alternate therapeutic
strategies under investigation to prevent C. difficile infection include the use of bacteriophages,
non-toxigenic C. difficile strains, and anti-virulence small molecules. Bacteriophages have been
approved for use to prevent foodborne pathogens (Hagens & Loessner, 2010). The critical part of
developing bacteriophage therapy against a bacterial pathogen is identifying and screening of a
specific phage that can selectively target the bacterium of interest. A specific four-phage
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combination (phiCDHM1-phiCDHM2-phiCDHM5-phiCDHM6) has been documented to be
effective in killing C. difficile(reference). Results from animal studies indicated administration of
bacteriophage combinations significantly reduced C. difficile colonization in the gut (Nale et al.,
2015). The major drawback in the use of bacteriophages is their fragile nuclear composition and
possibility of transfer of virulence factors between bacterial pathogens. Interestingly, phage taillike particles (PTLP) have been identified which can function similar to bacteriophages, but do not
transfer their DNA to the target cell (Sangster et al., 2015). However, further investigations are
required to confirm their practical use in human patients.
Another novel therapeutic approach against CDAD is the use of nontoxigenic C. difficile
for facilitating competitive exclusion of pathogenic C. difficile in the gut. C. difficile strain
VP20621 was found to be able to colonize the gastrointestinal tract of CDI infected patients
(Villano et al., 2012). Moreover, nontoxigenic C. difficile strain M3 (VP20621; NTCD-M3) has
been shown to reduce pathogenic C. difficile colonization when used with antibiotics such as
vancomycin and metronidazole (Gerding et al., 2015).
Since the toxins constitute the major virulence factor that is directly associated with C.
difficile associated colitis and clinical symptoms, a search for anti-virulence drugs that can reduce
the production or activity of C. difficile toxins A and B is an emerging research topic. Targeting
of the cysteine protease domain (CPD) located within the toxin protein has been found to be
effective in neutralizing C. difficile toxin-mediated pathology. Cysteine protease domain
inhibitors, such as ebselen, has been shown to possess activity against both TcdA, and TcdB and
prevented CDAD in mice (Bender et al., 2015). The increased incidence and severity of CDAD
along with high recurrence and relapse rates coupled with the emergence of antibiotic-resistant
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strains have incited significant research interest in the discovery of anti-virulence drugs against C.
diffficle. However, only a few compounds have been identified so far in this category.
6. Plant-derived phenols
6.1 Carvacrol
Carvacrol (CR) is phytophenol present in oregano oil obtained from Origanum vulgare, a
herb natively seen in Europe and the Mediterranean. Carvacrol is classified as Generally
Recognized as Safe (GRAS) and approved for use in foods by the FDA. The essential oil extracted
from O. vulgare has been found effective against various bacterial and fungal infections affecting
different body systems (Nostro & Papalia, 2011). Oregano oil and the active component carvacrol
have been found to possess significant antibacterial activity against various Gram-positive and
Gram-negative bacteria, including Helicobacter pylori, Staphylococcus aureus, Escherichia coli,
Streptococcus pneumoniae, and Streptococcus mutans, Enterobacter sakazakii, Haemophilus
influenza and methicillin-resistant S. aureus (Botelho et al., 2009; Chun et al., 2005; HerschMartinez et al., 2005). Moreover, CR has been found to exert inhibitory effect on spore outgrowth
of Clostridium perfringens (Juneja & Friedman, 2007).
Besides the antibacterial property, CR was found to possess various pharmacologic actions,
including anti-inflammatory, anti-diarrheal, anti-cancer, anti-adipogenic and neuroprotective
effects (Baser, 2008; Hotta et al., 2010; Kim et al., 2013; Lima et al., 2013; Yu et al., 2012).
Carvacrol was shown to exhibit strong anti-oxidant and anti-inflammatory properties by reducing
the accumulation of free-radicals and reducing the synthesis of inflammatory mediators (Hotta et
al., 2010). Carvacrol increased the anti-oxidant enzymes such as superoxide dismutase (SOD) and
glutathione (GSH) levels and reduced myeloperoxidase (MPO) and nitric oxide (NO) along with
inhibition of pro-inflammatory mediators such as inducible nitric oxide synthase (iNOS), and
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interleukin-1 beta (IL-1β) (Arigesavan & Sudhandiran, 2015). Suppression of the synthesis of
inflammatory mediators by CR is attributed to the inhibition of COX2 enzyme in macrophages
(Hotta et al., 2010) and induction of anti-inflammatory cytokine IL-10 (Lima et al., 2013).
6.2 Trans- cinnamaldehyde
Trans-cinnamaldehyde (TC) is one of the principal components of the bark extract of
cinnamon. It is also classified as GRAS by the FDA. Based on chronic toxicity studies, the U. S.
Flavoring Extract Manufacturers' Association reported that TC possesses a wide margin of safety
with no observed adverse effect levels (Adams et al., 2004). No identifiable genotoxic and
mutagenic effects were reported in these studies. Studies conducted in rats revealed that oral
supplementation of cinnamaldehyde resulted in 3.2 to16% recovery of the compound in excreta,
with 0.7% retention in the body tissues (Peters & Caldwell, 1994; Sapienza et al., 1993).
Trans-cinnamaldehyde exhibits antimicrobial activity against a wide range of pathogens,
including Gram-positive and Gram-negative bacteria (Friedman et al., 2002). Antibacterial effect
of TC against Listeria monocytogenes, S. aureus, Vibrio spp. and E. coli 0157: H7 has been
documented by various researchers (Brackman et al., 2008; Moon & Rhee, 2016; Upadhyay et al.,
2012; Upadhyay & Venkitanarayanan, 2016; Zhang et al., 2014). Interestingly, TC was found to
inhibit various pathogenic bacteria in vitro without causing any deleterious effect on the normal
gut microflora.

Trans-Cinnamaldehyde was found to reduce the growth of Salmonella

Typhimurium DTI04 and E. coli 0157: H7 with minimal inhibitory effects on Lactobacilli and
Bifidobacteria (Si et al., 2006). Moreover, TC has been found to be effective against biofilm
formation in Cronobacter sakazakii and uropathogenic E. coli (Amalaradjou et al., 2009;
Amalaradjou et al., 2010; Amalaradjou et al., 2011; Amalaradjou & Venkitanarayanan, 2011a;
Amalaradjou & Venkitanarayanan, 2011b). Furthermore, experiments conducted in our laboratory
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revealed that supplementation TC can reduce cecal colonization of S. Enteritidis in chickens and
inhibit critical virulence factors associated with its egg-borne transmission (Kollanoor Johny et
al., 2010; Kollanoor-Johny et al., 2012; Upadhyaya et al., 2013; Upadhyaya et al., 2015).
7. Potential food-borne transmission of C. difficile
7.1 Food animals as a source of C. difficile
Animals are an important source of human infectious microorganisms, especially those
causing enteric disease, which can spread following direct or indirect contact, through
environmental contamination or food (Steinmuller et al., 2006). For example, major foodborne
pathogens such as E. coli O157:H7, Listeria monocytogenes, and Salmonella species are carried
by food animals in their gastrointestinal tract, and are shed in feces (Altekruse et al., 1997), thereby
contaminating the animals’ hide, environment, water supply, and most importantly, the food
supply. Studies conducted by many investigators worldwide have indicated the occurrence of C.
difficile in a variety of food animals, and one of the reasons attributed to the increased reports of
human C. difficile infections is the rise in the isolation rates of the pathogen from animal reservoirs
(Indra et al., 2009; Rodriguez-Palacios et al., 2013a; Rupnik et al., 2008).
7.1.1 C. difficile infection and clinical signs in domestic animals
C. difficile associated diarrhea is reported in several animal species, which include pigs,
cattle, horses, dogs, hamsters, guinea pigs, ostriches and elephants (Keessen et al., 2011a). C.
difficile is a major cause of neonatal enteritis in pigs (Songer & Uzal, 2005). Affected piglets
usually exhibit yellow watery diarrhea or costipation with varying degrees of colitis seen at
autopsy (Songer & Anderson, 2006). C. difficile infection in foals and adult horses results in mild
disease with diarrhea to fatal hemorrhagic necrotizing enterocolitis (Keessen et al., 2011a). C.
difficile has been isolated from clinical cases of diarrhea reported in calves. However, a direct
27

correlation between diarrhea and C. difficile infection in calves, dogs, cats and poultry are poorly
understood.
7.1.2 Prevalence of C. difficile in food animals
In a study involving 600 piglets with enteritis, 35% of the animals were found infected
with C. difficile (Songer, 2004; Songer & Uzal, 2005). Another study examining piglets with
enteritis reported the presence of C. difficile in more than one-third of the animals and concluded
that C. difficile is potentially the most significant uncontrolled cause of neonatal diarrhea in pigs
(Songer & Anderson, 2006). Similarly, studies conducted in different countries suggested a high
prevalence of C. difficile in pigs, where the pathogen was genetically similar to some of the human
clinical isolates (Pirs et al., 2008; Silva et al., 2015; Squire & Riley, 2013; Thitaram et al., 2011a;
Thitaram et al., 2016; Yaeger et al., 2007). A study conducted in the US isolated C. difficile
ribotype 078 from 83% of neonatal pig samples and 94% of calf samples (Keel et al., 2007). In the
Netherlands, 078 C. difficile strains were detected from pigs and humans with comparable
phenotypic and genotypic characters (Debast et al., 2009). C. difficile has been isolated more
readily from young animals such as piglets and but adult animals prior to slaughter also tested
positive for the pathogen (Costa et al., 2012; Rodriguez et al., 2012; Silva et al., 2015). A study
conducted in the US with 875 food animals identified a comparatively lower prevalence rate of
<0.6% in poultry, cattle and pigs (Rodriguez-Palacios et al., 2014). In separate studies conducted
in different parts of the world, C. difficile has been detected in calves with varying prevalence rates
ranging from 1.8% in Slovenia (Pirs et al., 2008) to as high as 49% in Canada (Costa et al., 2012;
Weese, 2010). Furthermore, human hypervirulent C. difficile strain ribotype 027 has also been
isolated from calves (Rodriguez-Palacios et al., 2006). In the United States, a prevalence rate of
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25% in stool specimens collected from 253 diarrheic calves was reported, indicating that the
bacterium is an important pathogen of young animals (Hammitt et al., 2008).
Besides clinically sick animals with C. difficile, an important and problematic public
health significance is the shedding of the pathogen by clinically normal animals. These animals
could potentially constitute a large and undetected reservoir of the pathogen for contamination of
food, water and the environment (Weese, 2010). Researchers have established that calves can be
asymptomatic carriers of toxigenic C. difficile and may serve as a significant source (Hammitt et
al., 2008; Rodriguez-Palacios et al., 2013a). In study conducted in Austria, of the 59 fecal
specimens collected from healthy broiler chickens slaughtered, 5% of the samples tested positive
for C. difficile (Indra et al., 2009). Notably, 3.4% of these samples yielded toxigenic ribotypes 001
and 446, with the ribotype 001 being the second most frequently isolated strain implicated in
humans C. difficile infections in that country (Indra et al., 2009). In the same study, C. difficile
was isolated from 4.5 and 3.3% of the gut samples collected from adult cattle and pigs,
respectively. A study conducted by the U.S. Department of Agriculture in Texas revealed 2%
prevalence of C. difficile in commercial chickens prior to harvest (Harvey et al., 2011a). All these
aforementioned studies collectively suggest food animals as a potential source of C. difficile
relevant to public health.
7.2. Animal derived foods as a source of C. difficile
Since food animals are a potential source of C. difficile infection, animal-derived foods
could be one of the transmission routes of C. difficile from animals to humans. Moreover, detection
of genotypically similar and identical C. difficile strains implicated from human infections in food
animals raised concerns on the role of food as a source of human infections. Validating these
concerns, C. difficile spores have been isolated from a variety of raw and ready-to-eat meats
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intended for human consumption. The first report on the contamination of retail meat with C.
difficile was from Canada, where the bacterium was isolated from 21% of 53 ground beef and 14%
of 7 ground veal samples collected from five stores in two Canadian provinces (RodriguezPalacios et al., 2007). The toxigenic C. difficile North American pulsotype NAP1, toxinotype III
constituted 67% of the isolates from this study. A follow-up study by the same group of
investigators involving three Canadian provinces over a period of eight months, reported an
isolation rate of 6.7% and 4.6% in ground beef and veal chops, respectively (Rodriguez-Palacios
et al., 2009). Further, a series of studies conducted in Canada also found that C. difficile was present
in ground meats at the retail level, with a prevalence of 12% each in ground beef and ground pork
andnd 12.8% in chicken (Weese et al., 2010a; Weese et al., 2009). These initial findings
encouraged investigators around the world to screen retail meat for C. difficile (Lund & Peck,
2015; Rodriguez-Palacios et al., 2013a; Zidaric et al., 2010). In a study conducted in Slovenia, C.
difficile was detected from the fecal samples of 62% of chickens tested. An Austrian study revealed
a lower prevalence of 3% C. difficile prevalence in 100 ground meat samples collected at retail
(Jobstl et al., 2010). The first study investigating the prevalence of C. difficile in retail meat in the
US was conducted in Tucson, Arizona, which revealed a prevalence of 50% in ground beef, 15%
in summer sausage, 43% in ground pork, 44% in ground turkey, and 63% in braunschweiger
(Songer et al., 2009). It was found that 73% of the C. difficile isolates belonged to ribotype 087,
whereas the remaining isolates were of ribotype 027. Although a limited number of studies in the
U.S. investigated the prevalence of C. difficile in meats, an in-depth characterization of the food
isolates has not been performed. The prevalence of C. difficile in foods observed in previous
investigations varies from 0 to 40% (Harvey et al., 2011a; Limbago et al., 2012; Weese et al.,
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2009). However, no studies have been reported from the New England region, including
Connecticut, where the highest rate of CDAD was reported in 2010 and 2011 (Steiner et al., 2012).
Besides meats, C. difficile was also reported to be present in soil, water, raw vegetable
samples, and milk (Hensgens et al., 2012; Janezic et al., 2012a; Jobstl et al., 2010; Kotila et al.,
2013; Metcalf et al., 2010; Rodriguez-Palacios et al., 2013a). All these data taken together provide
further support to the likelihood of foods, especially those of animal origin, serving as a source of
C. difficile infection in humans.
In summary, C. difficile is a major cause of antibiotic-associated diarrhea in hospital
settings. C. difficile predominantly affects hospital inpatients undergoing prolonged antibiotic
therapy, which results in enteric dysbiosis, leading to C. difficile spore germination, pathogen
colonization in the intestine and subsequent toxin production. Therapeutic agents that inhibit
critical C. difficile virulence factors such as toxin production, sporulation, and spore outgrowth
without causing enteric dysbiosis could improve the clinical outcome of CDAD and prevent
relapse of the infection. Most of the antimicrobials, including anti- C. difficile antibiotics are found
to predispose patients to CDAD and its relapse by inducing gut dysbiosis. Moreover, the
emergence of antibiotic-resistant strains of hypervirulent C. difficile is reported worldwide,
warranting alternative therapeutic strategies. In addition, the detection of genotypically similar and
identical C. difficile strains implicated from human infections in foods and food animals suggests
the potential role of food as a source of community-associated C. difficile disease, which
necessitates detailed studies on the prevalence of C. difficile in foods and characterization of the
food isolates.
Based on published literature and preliminary research conducted in our laboratory, it is
hypothesized that meat is a potential source of multi-drug resistant C. difficile. Moreover, it was
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hypothesized that CR and TC reduce C. difficile virulence by reducing toxin production and
sporulation without deleteriously affecting the normal enteric flora. The specific objectives of this
dissertation include
1. To determine the prevalence of C. difficile in retail meat sold in Connecticut, and to
characterize C. difficile meat isolates by phenotypic and genotypic tests.
2. To investigate the effect of CR and TC on C. difficile toxin production in vitro.
3. To investigate the effect of CR on C. difficile sporulation and spore germination in vitro.
4. To study the effect of CR on C. difficile pathogenicity in a mouse model.
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Chapter III
The prevalence of C. difficile in retail meat sold in Connecticut, and characterization of a
C. difficile meat isolate by phenotypic and genotypic tests.
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Abstract
Clostridium difficile is a pathogen of significant public health concern causing a lifethreatening, toxin-mediated enteric disease in humans. The incidence and severity of the disease
associated with C. difficile have increased in the US with the emergence of hypervirulent strains
and community associated outbreaks. The detection of genotypically similar and identical C.
difficile strains implicated from human infections in foods and food animals indicate the potential
role of food as a source of community associated C. difficile disease. One hundred samples each
of ground beef, pork and chicken purchased from geographically distant grocery stores in
Connecticut were tested for C. difficile. Positive isolates were characterized by ribotyping,
antibiotic susceptibility, toxin production and whole genome sequencing. Of the 300 meat
samples, only two pork samples tested positive for C. difficile indicating a very low prevalence of
C. difficile in meat. The isolates were non-toxigenic; however, genome characterization revealed
the presence of several antibiotic resistance genes and mobile elements that can potentially
contribute to generation of multidrug resistant toxigenic C. difficile by horizontal gene transfer.
Further studies are warranted to investigate potential food-borne transmission of the meat isolates
and development of multi-drug resistance in these strains.
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1. Introduction
Clostridium difficile is a major cause of enteric disease in humans, with fecal-oral route as the
primary mode of transmission. C. difficile disease has been traditionally regarded as a nosocomial
infection in humans, especially in those receiving prolonged antimicrobial therapy (Hookman &
Barkin, 2009; McDonald et al., 2006). However, in recent years, an increase in the number and
severity of C. difficile infection in humans has been reported, particularly in those involving
communities outside the hospital environment and low risk subjects (McDonald et al., 2006;
Rupnik et al., 2009). Recent studies conducted by investigators worldwide have indicated the
occurrence of C. difficile in a variety of food animals. A rise in isolation rates of the pathogen
from animal reservoirs is one potential reason attributed to the increased reports of human C.
difficile infections (Rupnik et al., 2009; Thitaram et al., 2011b). In addition, C. difficile has been
isolated from raw and ready-to-eat meats at retail stores (Harvey et al., 2011b; Songer et al., 2009;
Weese et al., 2009; Weese et al., 2010b). The detection of genotypically similar and identical C.
difficile strains implicated from human infections in foods and food animals (Rodriguez-Palacios
et al., 2011; Weese et al., 2011) further strengthens the potential role of food as a source of
community associated C. difficile disease (Marsh et al., 2011; Songer et al., 2009). Although a
limited number of studies in the U.S investigated the prevalence of C. difficile in meats, an indepth characterization of the food isolates has not been performed. The prevalence of C. difficile
in foods observed in previous investigations varies from 0 to 40% (Harvey et al., 2011a; Limbago
et al., 2012; Songer et al., 2009; Weese et al., 2009). A report by the US Department of Health
and Human Services reported the highest rate of C. difficile associated hospitalizations in the New
England region in 2010 and 2011 (Steiner et al., 2012). The Centers for Disease Control and
Prevention (CDC) in collaboration with the Connecticut Department of Public Health (DPH) has
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initiated the Emerging Infections Program (EIP) for C. difficile surveillance with the objectives to
(1) determine the population-based incidence of community- and healthcare-associated C. difficile
infection, and (2) to characterize C. difficile strains that are responsible for infection in the
population under surveillance, with a focus on strains from community-associated cases.
Recent studies have suggested the possible emergence of new virulent or antibiotic resistant
C. difficile strains by horizontal gene transfer between toxigenic and non-toxigenic strains
(Brouwer et al., 2013). In addition, a closely related foodborne pathogen, C. perfringens was
found to acquire virulence by way of horizontal gene transfer in the gut environment (Kobayashi
et al., 2009; Popoff & Bouvet, 2013). Moreover, the CDC has listed C. difficile as one among the
three urgent threats in their recent report on emerging pathogens with antibiotic resistance (Steiner
et al., 2012). A genome-wide characterization of C. difficile food isolates would provide their
virulence and antimicrobial resistance profiles, besides indicating the genetic relatedness and
clonality between food and clinical isolates.
2. Materials and Methods
2.1 Sample collection and detection of C. difficile in meat
A total of 100 samples each of ground beef, ground pork and chicken wings were procured
from 23 geographically distant retail stores in Connecticut. All the procured samples were brought
to the laboratory on ice and processed within 24 h of receipt. Qualitative detection of C. difficile
was performed as described previously (Weese et al., 2010b), with modification for a higher
detection limit. Fifty grams each of ground beef, ground pork or a chicken wing were separately
added to 50 ml of C. difficile moxalactam-norfloxacin (CDMN, Oxoid, Hampshire, UK) broth
supplemented with 0.1% sodium taurocholate (Sigma-Aldrich, Inc., St. Louis, MO, USA), and
subjected to stomaching for 1 minute. After stomaching, 1 ml of the broth was pour-plated in
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duplicate to C. difficile moxalactam-norfloxacin (CDMN) agar, while the remaining broth-sample
mixture was incubated anaerobically at 37°C for 48 h. After incubation, an aliquot of the broth
was subjected to alcohol shock by adding 100% anhydrous ethanol for 1 h to eliminate the
vegetative bacteria. The broth was subsequently subjected to centrifugation at 4000 x g for 10
min, and the pellet was resuspended in 0.5 ml of phosphate buffered saline (PBS) and pour plated
in CDMN agar. The agar plates were incubated anaerobically at 37°C for 48 h. presumptive C.
difficile colonies were subcultured onto 7% horse blood agar and follow up identification of C.
difficile was done based on growth in CDMN agar, Gram’s staining, and colony characteristics.
The identity of C. difficile was further confirmed by L-proline aminopeptidase reaction (Pro Disc,
Remel, Lenexa, KS, USA) and PCR targeting tpi, a species-specific housekeeping gene of C.
difficile (Lemee et al., 2004).
2.2 Detection of toxins
The isolated C. difficile strains were screened for the presence of TcdA/B using a
commercially available enzyme immunoassay (EIA) C. difficile Tox A/B II kit (TechLab,
Blacksburg, VA, USA). The assay was previously optimized in our laboratory to quantitatively
detect toxin A/B using a standard curve method (Mooyottu et al., 2014e). The isolates were
revived on blood agar and an individual colony was transferred to 10 ml of Brain Heart Infusion
broth (BHI).

The cultures were incubated 24 h anaerobically at 37˚C and pelleted by

centrifugation. The supernatant was used for the EIA as per the manufacturer’s instructions. C.
difficile ATCC BAA 1870 was used as a positive control.
2.3 Antibiotic susceptibility tests
The isolated C. difficile strains were tested for the susceptibility to 10 antimicrobials
(ciprofloxacin, moxifloxacin, clindamycin, erythromycin, ampicillin, cefoxitin, metronidazole,
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rifampicin, and vancomycin) using the Etest (bioMérieux, Marcy l'Etoile, France) on Brucella
blood agar supplemented with hemin and vitamin K, according to the manufacturer's instructions.
The plates were incubated for 48 h at 37°C under anaerobic conditions, after which the minimum
inhibitory concentration (MIC) values were determined. The MIC breakpoints for clindamycin,
vancomycin, metronidazole and moxifloxacin were compared with those established by the CLSI
(Clinical and Laboratory Standards Institute (CLSI), 2007), European Committee for
Antimicrobial Susceptibility Testing (EUCAST) and British Society of antimicrobial
chemotherapy (BSAC) for C. difficile. For assessing the susceptibility for erythromycn, ampicillin,
tetracyclin, rifampicin, ciprofloxacin, cefoxitin and clindamycin, the epidemiological cutoff values
(ECOFF) recently established by the EUCAST obtained from the EUCAST MIC distribution
database (http://mic.eucast.org/Eucast2/SearchController/search.jsp?action=init) were used. C.
difficile ATCC 700057 was used as a control. The C. difficile isolates were considered multidrug
resistant (MDR) if they were resistant to three or more classes of antimicrobial agents (Schwarz et
al., 2010).
In addition, the antibiotic resistance profiles of the C. difficile isolates were compared with
one clinical isolate (ATCC BAA 1805) and non-toxigenic C. difficile strain ATCC 700057 using
antibiotic susceptibility discs (Oxoid, USA) in Brucella agar with 5% laked sheep blood
supplemented with hemin and vitamin K, as per CLSI directions. The antibiotics screened include
ampicillin, tetracycline, erythromycin, rifampicin, clindamycin, vancomycin, erythromycin,
cefoxitin, moxifloxacin and ciprofloxacin.
2.4 Toxin gene detection and ribotyping
A Chelex Resin-based DNA extraction kit (InstaGene Matrix, Bio-Rad, France) was used
for extracting the genomic DNA of C. difficile isolates. A multiplex PCR was carried out to detect
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the genes encoding toxins, TcdA, TcdB, CdtA, CdtB and TcdC deletion using previously published
primers (Antikainen et al., 2009). The PCR amplification was done using HotstarTaq (Qiagen,
Germany) PCR master mix, with thermocycler conditions: 10 min at 94°C, followed by 35 cycles
of 30 s at 94°C, 30 s at 60°C and 30 s at 72°C, and a final extension of 5 min at 72°C.
The PCR ribotyping was performed using a previously published protocol (Bidet et al.,
1999). The amplification reactions with designed primers were performed using HotstarTaq PCR
master mix (Qiagen, USA). The thermocycler conditions were 10 min at 94°C, followed by 35
cycles of 30 s at 94°C, 30 s at 57°C and 30 s at 72°C, and a final extension of 5 min at 72°C. The
PCR products were electrophoresed for 10 h at 75 V in 0.5X TBE using 3% agarose gel (MidSci,
St.Louis, MO, USA) stained with 0.5µg/mL ethidium bromide, and analyzed under UV light using
the BioDocIT Imaging System (UVP, LLC , Upland , CA , USA). The ribotype profiles were
analyzed with GelCompar II image analysis software (version 5.1; Applied Maths., Austin, TX,
USA).
2.5 Whole genome sequencing
The whole genome sequencing of the C. difficile isolates was done using the Illumina nextgeneration sequencing (NGS) technology (Illumina, San Diego, CA, USA). The genomic DNA
from C. difficile cultured on blood agar was extracted using the DNAeasy mini kit (Qiagen,
Germany), and multiplexed paired-end libraries (DNA fragments with each sample's DNA tagged
with a unique index) were generated. The DNA libraries were sequenced using sequencing-bysynthesis technology, 13 on the Illumina MiSeq platform, generating 300 base paired-end reads.
Contigs were assembled using CLC genomics workbench (CLC bio, Qiagen, Germany) and
annotated using Rapid Annotation Using Subsystem Technology (RAST, Rast. Nmpdr.org) and
NCBI's Prokaryotic Genomes Annotation Pipeline (PGAP). The draft sequence was submitted to
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the NCBI- National Center for Biotechnology Information (NCBI) whole genome shotgun (WGS)
database.
3. Results and discussion

In this study, we investigated the prevalence of C. difficile in 100 samples each of ground
beef, ground pork and chicken wings purchased from different geographic locations in
Connecticut. We followed direct plating and selective enrichment followed by alcohol shock in
CDMN agar. In order to increase the detection limit, a larger volume (1 ml) was pour plated
instead of plating 100 µl on to CDMN agar. Also, the whole meat-CDMN broth mixture was
enriched for further plating followed by an alcohol shock. Upon direct plating and enrichment,
40% of the samples showed colonies on CDMN agar plates. Gram’s staining of these colonies
revealed typical C. difficile morphology. In addition, proline amino peptidase reaction showed
positive reaction in around 20% of the samples. However most of the isolates were confirmed
negative for C. difficile by PCR for tpi. Clostridial species other than C. difficile, positive for
proline-amino peptidases activity (suggested to be C. acetobutyrolyticum or C. sporogenes by API
32 tests) were identified using API rapid ID 32 test. No C. difficile was isolated from any samples
of ground beef and chicken wings. Two of the pork samples tested positive for the presence of C.
difficile.
Our EIA results indicated the absence of toxins A and B in the isolated cultures. Multiplex
PCR for toxins confirmed that the pork isolates were non-toxigenic and negative for toxin A, B
and binary toxins. Evidently, no tcdC deletions were detected in the two pork isolates. TcdC is a
negative regulator in Pathogenicity Locus (PaLoc) of C. difficile. Hence TcdC deletion is
classically associated with increased toxin production in C. difficile strains (Dupuy et al., 2008;
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McDonald et al., 2005), and is a characteristic of hyper-virulent human toxigenic strains. However,
since the Connecticut C. difficile isolate (SG-12) described in this manuscript does not possess
PaLoc region in its genome, no bands could be observed in the PCR conducted for detection of
TcdC deletion. Both of the isolates were from the same brand and were from the same store. Nontoxigenic C. difficile has been isolated from human clinical and nonclinical sources, besides
environment as well as animal sources and food (Janezic et al., 2012b; Natarajan et al., 2013). In
healthy humans, the prevalence of C. difficile carriage has been reported as between 4 and 7.6%,
of which non-toxigenic strains accounted for 42–50% of the total isolates (Natarajan et al., 2013).
The sources and genetic relationship between human non-toxigenic C. difficile and that of animal
or environmental origin are poorly studied.
Ribotyping of the two pork isolates revealed that both samples are of the same ribotype,
which is unclassified and different from ribotypes 078, 027, 01, PA-01 and PA- 22 which were
previously reported in meat samples. Previous studies have shown that clinically relevant C.
difficile isolates have been isolated from pigs and piglets. C. difficile ribotype 078, which has been
reported to cause disease in humans, was isolated from pigs and pork products (Debast et al., 2009;
Keessen et al., 2011b; Peláez et al., 2013).

Also human toxigenic strains were reported from

ground pork and other products (Debast et al., 2009; Weese et al., 2011).
Antibiotic susceptibility tests revealed that the C. difficile isolated from pork samples were
resistant to an array of antibiotics (Table 1). Antibiotic profile of both pork isolates were identical
and thus we presented the data as a single isolate. The pork isolates were found to be resistant to
vancomycin (MIC > 2 µg/ml) according CLSI and EUCAST guidelines. The isolates were found
to be resistant to ciprofloxacin ((MIC > 32 µg/ml) and moxifloxacin (MIC > 6 µg/ml). The later
was assumed as per the EUCAST epidemiological cut off (ECOFF) values. Similarly, the isolates
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were not susceptible to cefoxitin even at a high concentration (MIC > 256 µg/ml). The MIC of
erythromycin (MIC > 3 µg/ml) indicated that the isolates were resistant to erythromycin according
to EUCAST ECOFF values. The isolates were highly resistant to tetracycline (MIC > 256 µg/mL)
whose ECOFF value was estimated as 0. 25 µg/ml according to EUCAST. The MIC of ampicillin
was found to be > 1.5 µg/ml which was similar to the previously published MIC of some clinical
isolates, and considered to be susceptible as per the CLSI MIC breakpoints for gram positive
anaerobes other than C. difficile. The disc diffusion test data revealed that the pork isolates are
more resistant (based on zone of inhibition) to vancomycin and ampicillin compared to the clinical
isolate (ATCC BAA 1805) tested. Interestingly, the isolates were found to be susceptible to
metronidazole (MIC > 0.19 µg/mL) and clindamycin (MIC > 1.5 µg/mL). Since the pork isolates
exhibited resistance to more than three groups of antibiotics, this isolate was considered as multidrug resistant. Resistance to multiple classes of antibiotics has been reported in meat and animal
C. difficile isolates in the USA (Harvey et al., 2011b; Rodriguez-Palacios et al., 2013b), with
isolation of multidrug resistant C. difficile from food animals and food products (Peláez et al.,
2013; Pirs et al., 2013).
Whole genome sequencing of one of the pork isolates results showed that the closest fully
sequenced relative was C. difficile 630, which is a multidrug resistant isolate of clinical origin.
Both isolates were found to be 100% identical in sequence and considered as a single isolate further
in this study. Interestingly, the phylogenetic tree (Complete phylogenetic tree is given as Figure.
1) constructed using all completed and draft genomes using the NCBI genome blast tool indicated
its close similarity to a swine toxigenic and presumably zoonotic strain C. difficile 824 and human
acute toxigenic strain Clostridium difficile CD44 (Figure. 1). Most of the closely related strains
were human hyper virulent clinical isolates. In addition, previously characterized non-toxigenic
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isolates such as CD37 (Brouwer et al., 2012) were genetically more distant from the Connecticut
pork isolate when compared to toxigenic isolates in its clade (Figure. 1).
The pork isolates did not possess the pathogenicity locus of C. difficile that contains toxin
and toxin regulatory genes, which is consistent with EIA and multiplex PCR data. However, it
possessed an array of antibiotic resistance genes including five vancomycin resistance genes, two
fluroquinolone resistance genes that included gyrA and gyrB, four tetracyclin resistance genes, two
beta lactamase genes, two macrolide resistance genes and multiple multidrug resistance efflux
pump genes. The genome data were found to be consistent with the antibiotic resistance profile
of the isolate. Since the pork isolates were found to be closely related to the fully sequenced multidrug resistant C. difficile 630, we compared antibiotic resistance genes of both strains (Table. 2)
using RAST. The Connecticut pork isolate was found to possess a higher number of antibiotic
resistant genes compared to C. difficile 630. Interestingly, Tn916, a conjugative transposable
element related to dissemination of antibiotic resistance in Gram positive bacteria (Spigaglia et al.,
2005) was also present in the Connecticut pork isolate.
The Tn916 transposon and related elements are widespread in many clinical strains of C.
difficile, and their ability to mobilize plasmids or other conjugative transposons could be relevant
for acquiring multiple antibiotic resistance and other virulence factors by C. difficile (Dong et al.,
2014; Spigaglia et al., 2005).
In addition to antibiotic resistance genes, the pork isolates also possessed additional
resistance to metals such as zinc and mercury, unlike C. difficile 630 strain. Two unique multidrug
resistance genes (Multidrug and toxin extrusion (MATE) family efflux pump and Multidrug-efflux
transporter, major facilitator superfamily (MFS)) were identified in the pork isolate compared to
C. difficile 630 strain.
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Although the prevalence of C. difficile detected in meat samples (2 out of 300 samples
tested) was very low, and the strains isolated were non-toxigenic; the presence of multidrug
resistance genes and transposable elements raise a significant concern. Since C. difficile genome
is highly mobile (Sebaihia et al., 2006), horizontal gene transfer and large-scale recombination of
core genes has shaped the C. difficile genome over both short and long time scales (Dingle et al.,
2013). Recent studies indicate that non-toxigenic strains of C. difficile can become toxigenic by
horizontal gene transfer (Brouwer et al., 2013). The major virulence determinants are Clostridial
toxins, toxin A (tcdA) and toxin B (tcdB), encoded within the pathogenicity locus (PaLoc). PaLoc
is variably present, even among closely related strains, and thus resembles a mobile genetic
element (Dingle et al., 2013). This raises the concern over the potential generation of toxigenic
variants of multidrug resistant nontoxigenic strains of C. difficile in the gut. The PaLoc acquisition
and loss are common in non-toxigenic and toxigenic strains, as indicated by existence of closely
related toxigenic and non-toxigenic strains. Phylogenetic information of the pork isolate indicated
its close relatedness to the toxigenic isolates in its clade. Conversely, the presence of conjugative
transposons like Tn 916 in the pork isolates pose a concern because they confer antibiotic
resistance and virulence factors to clinical strains of C. difficile in the gut. The presence of multidrug resistant C. difficile in foods can potentially facilitate intermixing of toxigenic and nontoxigenic strains in the gut which could lead to the emergence of new multidrug resistant C.
difficile strains.
The low occurrence of C. difficile in meat is consistent with a previous studies (Limbago
et al., 2012). However, the source of contamination of C. difficile in retail meat is not known,
which could be from meat processing facilities, facility personal or the animals (Harvey et al.,
2011a; Jöbstl et al., 2010; Rodriguez-Palacios et al., 2013b).
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4. Conclusion
In summary, we confirmed that C. difficile occurs at very low levels in raw meat sold in
Connecticut. The isolates were non-toxigenic, but found to have an array of antibiotic resistance
genes and mobile elements, which can potentially contribute to the generation of multi-drug
resistant toxigenic strains. Further studies are warranted to delineate the source of contamination
and the effect of cooking and other processing operations on the viability of C. difficile spores in
meat.
Nucleotide sequence accession numbers
This Whole Genome Shotgun project has been deposited in DDBJ/EMBL/GenBank under
accession number JFAF00000000. The version described in this paper is the first version,
JFAF01000000. http://www.ncbi.nlm.nih.gov/nuccore/JFAF00000000
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Table 1. Minimum inhibitory concentrations (MIC) values of 10 antimicrobials against the pork
isolate of C. difficile (SG-12) determined by Etest, and respective Clinical & Laboratory Standards
Institute (CLSI) break points and ecological cut-off values (ECOFF) established by The European
Committee on Antimicrobial Susceptibility Testing (EUCAST). Zone of inhibition for same
antimicrobials for SG-12, clinical isolate ATCC 1870 and non-toxigenic isolate ATCC 700057
estimated using disc diffusion method are also determined.

MIC values and comparative antibiotic resistance profile of C. difficile pork isolate (SG-12).

Antibiotic

MIC
(SG12)
μg/ml(Etest)

CLSI
break
point
μg/ml

EUCAST
ECOFF(μg/ml)
<

Zone of
inhibition
(SG-12)
mm

Zone of inhibition
(ATCC BAA 1870)
mm

Zone of inhibition
(ATCC 700057)
mm

Ciprofloxacin

> 32

–

–

0

0

0

Moxifloxacin

6

–

4

2

2

0

Vancomycin

>2

>2

2

23

35

16

Tetracyclin

> 256

–

0.25

7

38

10

Erythromycin

3

–

2

23

0

38

Cefoxitin

> 256

–

–

0

0

0

Clindamicin

> 1.5

–

16

1.2

7

0

Metronidazol

> 1.9

2

2

25

2

20

Rifampicin

< 0.02

–

0.004

30

25

26

Ampicillin

1.5

–

–

23

25

27

Table 2. Antibiotic resistance genes identified in the genome of pork isolate SG-12 and multidrug
resistant C. difficile 630 (CD-630). The presence or absence of antibiotic resistance genes in
annotated C. difficile pork isolate (SG-12) were compared with multidrug resistant C. difficile 630
(CD-630) reference genome using RAST.

97

Antibiotic resistance genes identified in C. difficile
pork isolate (SG-12) and reference strain C. difficile 630 (CD-630).
Antibiotic

Resistance genes

SG-12

CD630

Vancomycin

Vancomycin B-type
resistance protein
VanW

+

+

Vancomycin Teicoplanin A-type resistance protein VanA

+

+

Vancomycin response regulator VanR

+

+

Sensor histidine kinase VanS

+

+

Streptococcus pneumoniae Vancomycin Tolerance Locus Vex 2

+

−

Streptococcus pneumoniae Vancomycin Tolerance Locus Vex 3

+

−

Two-component response regulator VncR

+

−

Sensor histidine kinase VncS

+
DNA gyrase subunit
A

−

+
Tetracycline
resistance protein
TetM

+

+

Beta-lactam antibiotics

+
Beta-lactamase
repressor BlaI

Regulatory protein BlaR-1

+

+

Beta-lactamase BL

+
Macrolide efflux
protein

−

+

Multidrug resistance

+
Multi antimicrobial
extrusion protein
(Na(+)/drug
antiporter)<comma>
MATE family of
MDR efflux pumps

Multidrug and toxin extrusion (MATE) family efflux pump
YdhE/NorM<comma> homolog

+

−

Multidrug-efflux transporter<comma> major facilitator superfamily (MFS)

+

−

Fluoroquinolones
DNA gyrase subunit B

Tetracycline
Translation elongation factor G

Macrolides
Macrolide glycosyltransferase
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+

+

+

+

+

+

+

−

+

+

Figure 1. Phylogenetic tree constructed by genome blast (NCBI) demonstrating relationship
between the pork isolate SG-12 and other complete and draft genomes. Phylogenetic tree was
generated by minimum evolution method.
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Chapter IV
Effect of carvacrol (CR) and trans-cinnamaldehyde (TC) on C. difficile toxin production,
cytotoxicity and toxin gene expression

Published in International Journal of Molecular Sciences, 2014;15(3):4415-30
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Abstract
Clostridium difficile is a nosocomial pathogen that causes a serious toxin-mediated enteric disease
in humans. Reducing C. difficile toxin production could significantly minimize its pathogenicity
and improve disease outcomes in humans. This study investigated the efficacy of two, food-grade,
plant-derived compounds, namely trans-cinnamaldehyde (TC) and carvacrol (CR) in reducing C.
difficile toxin production and cytotoxicity in vitro. Three hypervirulent C. difficile isolates were
grown with or without the sub-inhibitory concentrations of TC or CR, and the culture supernatant
and the bacterial pellet were collected for total toxin quantitation, Vero cell cytotoxicity assay and
RT-qPCR analysis of toxin-encoding genes. The effect of CR and TC on a codY mutant and wild
type C. difficile was also investigated. Carvacrol and TC substantially reduced C. difficile toxin
production and cytotoxicity on Vero cells. The plant compounds also significantly down-regulated
toxin production genes. Carvacrol and TC did not inhibit toxin production in the codY mutant of
C. difficile, suggesting a potential codY-mediated anti-toxigenic mechanism of the plant
compounds. The antitoxigenic concentrations of CR and TC did not inhibit the growth of beneficial
gut bacteria. Our results suggest that CR and TC could potentially be used to control C. difficile,
and warrant future studies in vivo.
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1. Introduction
Clostridium difficile is a gram-positive, spore-forming, anaerobic bacterium that causes a
toxin-mediated enteric disease in humans (Weese, 2010). More than 300,000 cases of C. difficileassociated disease (CDAD) are reported annually in the United States, resulting in approximately
US$3 billion of health care costs (Ghose et al., 2007; Wilkins & Lyerly, 2003). The emergence of
a hypervirulent strain, NAP1/ribotype 027, that produces increased levels of toxins and a severe
form of the disease in humans has been reported (Blossom & McDonald, 2007; Hookman &
Barkin, 2009; Sunenshine & McDonald, 2006). C. difficile predominantly affects long-term
hospital inpatients and the elderly undergoing prolonged antibiotic therapy (Hookman & Barkin,
2009). Prolonged antibiotic therapy results in the disruption of the normal enteric microflora,
leading to the germination of C. difficile spores and pathogen colonization in the intestine with
subsequent production of toxins (Dial et al., 2005). The toxins, TcdA and TcdB, act as glucosyl
transferases that inactivate the Rho family GTPases associated with F-actin regulation, and
consequently cause disruption of the cytoskeleton and intestinal epithelial tight junctions (Keel &
Songer, 2006; von Eichel-Streiber et al., 1999). This leads to an inflammatory response with the
release of cytokines and leukotrienes, causing pseudomembrane formation and watery diarrhea
(Hookman & Barkin, 2009; McDonald et al., 2006; Sunenshine & McDonald, 2006). The genes
tcdA and tcdB, which encode the C. difficile toxins TcdA and TcdB, respectively, along with the
genes encoding TcdR, an RNA polymerase sigma factor needed for maximal expression of tcdA
and tcdB, TcdC, an antagonist of TcdR, and TcdE, a holin-like protein needed for toxin excretion,
constitute the “pathogenicity locus” in C. difficile (McDonald et al., 2006). Expression of the
pathogenicity locus is controlled by a number of environmental factors, including the availability
of rapidly metabolizable carbon sources, a regulation mediated by the global regulator CcpA
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(Antunes et al., 2011a; Antunes et al., 2012) and the intracellular pools of the branched-chain
amino acids and GTP, mediated by the global regulator CodY (Dineen et al., 2007; Dineen et al.,
2010). Although exposure to broad-spectrum antibiotics predisposes patients to CDAD by
disrupting the normal gut flora (Bartlett, 1992; O'Connor et al., 2004), antibiotics are still the
primary line of treatment for patients who have contracted the disease. In addition, the emergence
of antibiotic resistance in hypervirulent strains of C. difficile is increasingly reported worldwide
(Prabaker & Weinstein, 2011; Spigaglia et al., 2011). Since C. difficile toxins are the major
virulence factors responsible for the pathogenesis of CDAD, identification of alternative
therapeutic agents that inhibit C. difficile toxin production without affecting the normal
gastrointestinal flora or exacerbating bacterial antibiotic resistance could be a potentially viable
approach for controlling CDAD.
Historically, plants have been used for treating various diseases in traditional medicine (Johny
et al., 2010). Carvacrol (CR) is a monoterpenoid phenol present in oregano and thyme oils. Diverse
pharmacological actions of CR, including antimicrobial and anti-inflammatory properties, have
been previously demonstrated (Baser, 2008). Trans-cinnamaldehyde (TC) is an aromatic aldehyde
present as a major component of the bark extract of cinnamon. Previous research conducted in our
laboratory revealed that sub-inhibitory concentrations (SICs; the concentrations that do not inhibit
bacterial growth) of TC and CR increased the sensitivity of multi-drug resistant Salmonella
Typhimurium DT 104 to antibiotics by down-regulating antibiotic resistance genes and the efflux
pump, tolC (Johny et al., 2010). In addition, we previously observed that TC inhibited biofilm
synthesis and virulence in uropathogenic Escherichia coli (Amalaradjou et al., 2010; Amalaradjou
et al., 2011). The objective of this study was to investigate the effect of sub-inhibitory
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concentrations (SICs) of TC and CR on toxin production and cytotoxicity of C. difficile in vitro,
and delineate the potential mechanism(s) behind their effect.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
Four hypervirulent C. difficile isolates (ATCC# BAA 1870, 1053, 1805 and UK1) were grown
in brain heart infusion broth (BHI) supplemented with 5% yeast extract (Difco, Sparks, MD, USA)
in a Whitley A35 anaerobic work station (Microbiology Inc., Frederick, MD, USA) in the presence
of 80% nitrogen, 10% carbon dioxide and 10% hydrogen at 37 °C for 24 h. The bacterial
population was titered by plating 0.1 mL portions of appropriate dilutions on BHI agar and
Clostridium difficile moxalactum norfloxacin (CDMN) agar (Oxoid, Hampshire, UK)
supplemented with 5% horse blood, under strict anaerobic conditions at 37 °C for 24 h. In addition,
seven selected beneficial enteric bacteria obtained from the USDA-ARS culture collection, Peoria,
IL (Lactobacillus brevis, L. reuterii, L. delbrueckii bulgaricus, L. fermentum, L. plantarum,
Bifidobacterium bifidum, and Lactococcus lactis lactis) were separately grown in de Man, Rogosa
and Sharpe (MRS) broth (Difco, Sparks, MD, USA) under anaerobic conditions at 37 °C. The
titers of the cultures were determined by plating 0.1 mL portions of appropriate dilutions on MRS
agar (Difco, Sparks, MD, USA) with incubation at 37 °C for 24 h. The cultures were sedimented
by centrifugation (3600 g, 15 min, 4 °C), and the pellets were washed twice, and resuspended in
sterile phosphate-buffered saline (pH 7.3), and used as the inoculum.
2.2. Plant Compounds and SIC Determination
The SIC of TC and CR was determined as previously described (Johny et al., 2010). Fifty ml
of BHI supplemented with 5% yeast extract was inoculated separately with ~5.0 log10 CFU of each
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C. difficile isolate, followed by the addition of 1 to 10 µL of TC or CR (Sigma-Aldrich, St. Louis,
MO, USA) with an increment of 1 µL. The cultures were incubated at 37 °C for 24 h, and bacterial
growth was determined by measuring the optical density at 600 nm. The highest concentration of
each plant compound that did not inhibit bacterial growth after 24 h of incubation was selected as
its respective SIC (Sub Inhibitory Concentration) for this study.
Similarly, the effect of SIC of TC and CR on the growth of the aforementioned beneficial gut
bacteria was determined by culturing them separately in 10 mL of MRS broth under anaerobic
conditions at 37 °C with or without the plant compounds for 24 h. The growth of each culture was
determined by measuring optical density at 600 nm, and plating on MRS agar.
2.3. Effect of Plant Compounds on C. difficile Toxin Production and Cytotoxicity
Brain Heart infusion broth, with or without the SIC of TC or CR was inoculated (105 CFU/mL)
separately with each C. difficile isolate, and incubated at 37 °C for 48 h anaerobically as before.
The culture supernatant was collected at 15, 24, and 48 h of incubation for total toxin A and B
quantitation by ELISA (Merrigan et al., 2010) and for determining cytotoxicity on Vero cells. The
bacterial pellets were harvested at
6 h and 12 h for RNA isolation and RT-qPCR analysis of C. difficile genes associated with
toxin synthesis.
2.4. ELISA for Total Toxin A and B
The amount of toxin in the culture supernatant was quantified using the Wampole Tox A/B II
kit (TechLabs, Inc., Blacksburg, VA, USA), as described by Merrigan et al. (Merrigan et al., 2010).
Purified toxin B (Sigma Aldrich, St. Louis, MO, USA) was used to plot a standard curve. The
culture supernatants were diluted and ELISA was performed according to the manufacturer’s
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instructions. The optical density was measured at 450 nm, compared with the linear range of
standard curve, and total toxin concentration was estimated.
2.5. Cytotoxicity Assay
The effect of CR and TC on the cytotoxicity of C. difficile culture supernatant was estimated
by Vero cell cytotoxicity assay, as described previously (Baines et al., 2005). C. difficile culture
supernatant was serially diluted (1:10) and added onto Vero cell monolayers in 96-well microtiter
plates. The plates were incubated at 37 °C in a 5% CO2 environment for 48 h, and examined under
an inverted microscope. Positive reactions were indicated by the characteristic rounding of Vero
cells accompanied by parallel neutralization of cytotoxicity with Clostridium sordellii antitoxin
(TechLabs, Inc., Blacksburg, VA, USA). The cytotoxicity titer was expressed as the reciprocal of
the highest dilution that caused more than 80% cell rounding.
2.6. Real Time Quantitative PCR (RT-qPCR)
In order to determine the effect of CR and TC on C. difficile genes involved in toxin synthesis,
total RNA was isolated from the early stationary phase (12 h) cultures (Blossom & McDonald,
2007). The culture supernatant was harvested by centrifugation at 3000 × g for 10 min at 4 °C. The
bacterial pellet was resuspended in RNAwiz solution (Ambion, Austin, TX, USA), flash frozen in
liquid nitrogen, and stored at −80 °C. Total RNA extraction was performed using the Ambion
RiboPure Bacteria RNA kit (Ambion, Austin, TX, USA) according to the manufacturer’s
instructions, followed by DNase I digestion using Turbo DNase I (Ambion). The RNA obtained
after each DNase I digestion was purified further using the Qiagen RNeasy RNA column
purification kit, according to the manufacturer’s instructions (Qiagen, Germantown, MD, USA).
The cDNA was synthesized using the Bio-Rad iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA, USA). RT-qPCR analysis of the genes associated with toxin production was performed using
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published primers for Paloc genes (Vohra & Poxton, 2011) normalized against 16S rRNA gene
expression. Twenty-five μL reactions were performed in triplicate using iTaq SYBR (Bio-Rad,
Hercules, CA, USA). The relative fold change in gene expression was calculated using the 2−ΔΔCt
method (Livak & Schmittgen, 2001).
2.7. Construction of a codY Mutant of C. difficile Strain UK-1 and the Effect of Plant
Compounds on codY Mutant and Parental Strains
The pJS107 plasmid (Francis et al., 2013) was used as a TargeTron vector to introduce
mutations into the NAP1/027 C. difficile strain UK-1. The group II intron insertion sites for C.
difficile

codY

were

identified

using an algorithm that can be found at http://dna.med.monash.edu.au/~torsten/intron_site_finder/.
The intron fragment was generated by PCR using primers oLB178 (TGAACGCAAGTTTCTA
ATTTCGATTGTAGTTCGATAGAGGAAAGTGTCT),oLB179(AAAAAAGCTTATAATTAT
CCTTAACTACCGTAGTAGTGCGCCCAGATAGGGTG),

oLB180

(CAGATTGTACAAATGTGGTGATAACAGATAAGTCGTAGTATATAACTTACCTTTCTT
TGT) and EBS-Universal (CGAAATTAGAAACTTGCGTTCAGTAAAC), and a 1:1 mixture of
pBL64 and pBL65 as template (Bouillaut et al., 2013) and then cloned at the HindIII and BsrGI
sites of pJS107, yielding pBL103. pBL103 was then introduced into B. subtilis strain BS49 by
transformation. Strain BS49 carries a conjugative transposon, Tn916, integrated into its
chromosome and serves as a donor in conjugation with C. difficile. Conjugation experiments were
carried out as described previously (Carter et al., 2011). C. difficile transconjugants were selected
on thiamphenicol (10 µg/mL) and then screened for the presence of Tn916 by assaying tetracycline
resistance (10 µg/mL). Thiamphenicol-resistant, tetracycline-sensitive (plasmid-containing,
transposon-negative) transconjugants were selected for further use. Potential TargeTron mutants
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were identified by plating on lincomycin (20 µg/mL) and screening for the insertion of the intron
into C. difficile codY by PCR using primers specific for full-length C. difficile codY. (oLB205,
TGAGCATGCTTAATGATGATGATGATGATGTTGATTGTTTTTTAATTTTTTTAATTCA
TC; and oLB206, TATCCGGAATTCTGAGGAGATGATTAAATGGC), the 5' intron insertion
site and the 3' intron insertion site and a positive clone, strain LB-CD16, was identified. A Southern
blot was performed as previously described (Bouillaut et al., 2013) to confirm that the mutant
contained a single insertion of the intron.
The role of codY on the anti-toxigenic effect mediated by the plant compounds was investigated
by quantifying toxin production and expression of toxin-associated genes in CR- and TC-treated
codY mutant and wild type strains of C. difficile. Brain Heart infusion broth, with or without the
SIC of TC or CR was separately inoculated (105 CFU/mL) with UK1 or LB16, and incubated at
37 °C for 48 h, as described previously. The culture supernatants were collected at 24 and 48 h of
incubation for total toxin A and B quantitation by ELISA. In addition, the bacterial pellets were
harvested at 12 h for RNA isolation and RT-qPCR analysis.
2.8. Statistical Analysis
All experiments had duplicate samples and the study was repeated three times. The data were
analysed using the PROC-MIXED procedure of SAS v. 9.3 (SAS Institute Inc, Cary, NC, USA).
Differences between the means were considered significantly different at p < 0.05.
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3. Results
3.1 Sub-Inhibitory Concentrations of CR and TC
The SICs of CR and TC were found to be 0.60 mM (1.0 mg/L) and 0.38 mM (0.5mg/L),
respectively. These concentrations of plant compounds did not inhibit the growth of all C. difficile
isolates including CodY mutant and parental strains after 24 h incubation at 37 °C. In addition, the
OD600 values for the seven selected beneficial bacterial isolates cultured in the presence of SICs
of CR and TC were not significantly different from their respective controls (bacteria grown
without CR or TC, Figure 1). This indicated that the concentrations of CR and TC used in this
study were non-inhibitory to the growth of C. difficile as well as the seven selected beneficial
bacteria.
3.2 Effect of CR and TC on C. difficile Toxin Production
The effect of CR and TC on C. difficile toxin production was determined by ELISA, as
described previously (Merrigan et al., 2010). Carvacrol and TC significantly reduced toxin
production in all three C. difficile isolates at 24 and 48 h (p < 0.05) compared to their controls. At
48 h, CR and TC inhibited the toxin production by approximately 60% and 80%, respectively in
isolates BAA 1870 and 1053 (Figure 2A,B). In isolate BAA 1805, CR and TC reduced toxin
production by approximately 55% at 48 h, compared to the control (Figure 2C). In isolates BAA
1870 and 1503, TC was more effective in reducing the toxin production than CR (p < 0.05) (Figure
2A,B), whereas both compounds exerted a similar inhibitory effect on toxin production in BAA
1805 after 48 h of incubation (Figure 2C).
3.3. Effect of CR and TC on C. difficile Toxin-Mediated Cytotoxicity
To determine the efficacy of TC and CR in reducing C. difficile-induced cytopathic effects, a
cytotoxicity assay was conducted on Vero cells following a previously published protocol (Baines
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et al., 2005). Exposure to TC and CR significantly reduced the ability of C. difficile culture
supernatant to produce cytotoxicity on Vero cells compared to culture supernatants of untreated
cells (p < 0.05). The cytotoxicity titer in the cells inoculated with CR- and TC-treated C. difficile
culture supernatant was reduced by ~90% at 48 h in comparison to that in the control (Figure 3).

3.4. Effect of CR and TC on C. difficile Toxin Genes
To investigate if the observed reduction in C. difficile toxin production was due to modulation
of the expression of toxin-associated genes, transcriptional analysis by RT-qPCR (Real timequantitative polymerase chain reaction) of the genes known to be involved in toxin production and
regulation was performed. The data revealed a modulation of C. difficile toxin regulatory genes by
CR and TC at early stationary phase (12 h) (Figures 4 and 5). Carvacrol significantly downregulated (p < 0.05) the expression of toxin genes tcdA and tcdB in all three isolates of C. difficile
(p < 0.05) by ~2.5 fold (Figure 4A,C). However, in isolate BAA 1053, the genes were downregulated by 15 to 25 fold (Figure 4B). Similar results were obtained in C. difficile isolates exposed
to TC (Figure 5A,B). However, in isolate BAA 1805, no significant difference was observed in
comparison to the control (Figure 5C). A significant down-regulation was also observed in the
expression of the toxin excretion gene tcdE and the positive regulator tcdR in two C. difficile
isolates (ATCC # BAA 1870, 1053) treated with CR and TC (Figures 4 and 5). In isolates BAA
1870 and 1805, trans-cinnamaldehyde treatment increased expression of tcdC, which encodes the
TcdR antagonist (Figure 5A,B). Up-regulation of tcdC was observed in CR-treated BAA 1870 and
1053 as well (Figure 4A,B).
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3.5. Effect of CR and TC on a codY Mutant of C. difficile
In this experiment, we treated the C. difficile codY mutant (LB-CD16) and its parental strain,
UK-1, with the SIC of CR or TC, and determined their effects on toxin production and toxin gene
expression. The total toxin quantitation by ELISA (Enzyme Linked Immunosorbent Assay)
revealed a significant reduction in toxin production in CR- or TC-treated UK-1 (p < 0.05)
compared to the control (Figure 6). However, in a codY mutant, the level of toxin production in
the absence of drug was higher than in the parent strain and neither CR nor TC caused any
inhibition of toxin production. In fact, TC treatment enhanced the toxin production in the codY
mutant strain significantly (p < 0.05) compared to the untreated control. Thus, in the absence of
functional CodY protein, neither CR nor TC could inhibit toxin production.
RT-qPCR analysis of the toxin genes in the codY mutant strain and its parent revealed a trend
in gene expression similar to that seen for toxin production (Figure 7). A significant downregulation of tcdA and tcdB was observed in strain UK-1 treated with CR or TC (p < 0.05).
However, consistent with the ELISA results, CR and TC did not cause any down-regulation of the
tcdA and tcdB genes in the codY mutant (p < 0.05). Specifically, no significant change in the
expression of tcdA, tcdB, tcdC and tcdR was observed in the codY mutant treated with CR.
However, TC treatment resulted in a significant up-regulation of tcdA and tcdB in the mutant (p <
0.05). These data collectively suggest that the SICs of CR and TC were unable to exert any
inhibitory effect on the toxin-encoding genes in the absence of a functional codY.
4. Discussion
C. difficile colonizes the large intestine of patients undergoing prolonged antibiotic therapy, and
produces toxins TcdA and TcdB, resulting in CDAD. C. difficile toxins lead to inflammation in
the intestine, increased epithelial permeability (Castagliuolo et al., 1998; Feltis et al., 2000; He et al.,
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2002), enhanced cytokine and chemokine production (Castagliuolo et al., 1998; He et al., 2002),
neutrophil infiltration (Kelly et al., 1994) and the release of reactive oxygen intermediates (He et
al., 2002), thereby causing direct damage to the intestinal mucosa (Ng et al., 2010). Therefore,
reducing toxin production by C. difficile is critical in controlling CDAD.
A potential alternate strategy for controlling microbial infections is the use of anti-virulence
drugs. This class of drugs aims at reducing bacterial virulence rather than inhibiting bacterial
growth (Rasko & Sperandio, 2010) and presents a lesser selective pressure for development of
bacterial antimicrobial resistance (Cegelski et al., 2008; Hughes & Sperandio, 2008; Hung et al.,
2005). Therefore, in the current study, we investigated the efficacy of SICs of CR and TC as
alternative therapeutic agents that can ameliorate CDAD pathology by reducing C. difficile toxin
production without affecting the growth of the normal intestinal flora. Since the SICs of
antimicrobials, including antibiotics, can modulate bacterial gene expression and physicochemical functions, they have been used for studying effects on bacterial gene expression and
virulence (Tsui et al., 2004).
In the current study, we found that the SICs of CR and TC for C. difficile growth did not inhibit
the growth of seven different species of bacteria commonly found in the human gastrointestinal
tract although CR and TC have antimicrobial activity at higher concentrations. The tested gut
bacteria included Lactobacilli and Bifidobacteria, which are the major groups of beneficial gut
flora that play a significant role in maintaining normal gut health (Rupa & Mine, 2012). Previous
studies have reported that low concentrations of CR and TC exerted no adverse effects on
endogenous bacterial populations, including Lactobacilli and Bifidobacteria, in pigs and poultry
(Jamroz et al., 2005; Si et al., 2006).
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Our ELISA results indicated that both plant compounds decreased the total toxin production in
all three C. difficile isolates obtained from the ATCC, compared to their untreated control cultures
(Figure 2). In addition, culture supernatants from TC- or CR-treated cells of all three strains had
significantly reduced cytotoxic effects on Vero cells (Figure 3), confirming the ELISA results.
Previously, Ultee and Smid (2001) reported that sub-MIC concentrations of CR decreased toxin
production in Bacillus cereus (Ultee & Smid, 2001). Moreover, prior research conducted in our
laboratory revealed that plant compounds, including CR and TC, reduce the virulence of Listeria
monocytogenes by decreasing its attachment to and invasion of cultured human intestinal epithelial
and brain micro-vascular endothelial cells by modulating the expression of several virulence
factors, including the global regulator, prfA (Upadhyay et al., 2012). Since SICs of CR and TC
were used in the experiments, the reduction observed in C. difficile toxin production in the treated
samples was not due to growth inhibition of the bacterium by the plant compounds, but could be
due to their potential abilities to modulate the expression of virulence genes associated with toxin
production. Therefore, we used RT-qPCR to determine the effect of TC and CR on the
transcription of major genes reported to play a role in toxin synthesis and secretion. Our RT-qPCR
data revealed a 3-to-20-fold reduction in the expression of toxin-encoding genes tcdA and tcdB in
strains BAA 1870 and BAA 1053. Furthermore, tcdR, which encodes a factor essential for highlevel toxin production, was down-regulated 3-to-40-fold by CR and TC in those strains (Figures 4
and 5). Down-regulation of TcdR is known to lead to reduced toxin production (Mani et al., 2002).
Down-regulation of tcdE was also observed in these C. difficile isolates treated with CR or TC
(Figures 4 and 5). Multiple studies have demonstrated that tcdE is critical for toxin release from C.
difficile, helping to explain the reduced amount of toxins in CR- and TC-treated culture
supernatants. In strain BAA 1805, however, the correlation between toxin and holin gene
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expression and toxin production was less clear suggesting that in this strain the modulation of toxin
synthesis is mediated by a different mechanism than in other strains. Our results show that the
compounds block toxin production in all strains, albeit to different extents, and that this effect can
be attributed to decreases in toxin gene transcription in all strains except in the case of strain BAA
1805 in presence of TC.
CodY, a global regulatory protein that senses the intracellular levels of branched-chain amino
acids and GTP, monitors the nutritional status and regulates metabolism and stress responses in
Gram-positive bacteria (Dineen et al., 2010; Guedon et al., 2001; Pohl et al., 2009). In addition,
CodY acts as a global regulator of virulence; a codY deletion results in enhanced virulence in
Staphylococcus aureus and other species (Montgomery et al., 2012; Pohl et al., 2009; Rivera et
al., 2012; Stenz et al., 2011). In C. difficile, CodY is a potent repressor of tcdR, thereby preventing
expression of the Paloc genes when cells are growing rapidly (Dineen et al., 2007; Dineen et al.,
2010). Previous studies have shown increased expression of toxin genes in a codY mutant of C.
difficile (Dineen et al., 2007; Dineen et al., 2010). Our results show that CR and TC reduce toxin
production and pathogencity locus gene expression in NAP1/027 strain UK-1, but not in a codY
null mutant of UK-1. In fact, TC caused hyperexpression of toxin locus genes in the codY mutant
strain. In a codY mutant strain, the compounds lose their effectiveness as inhibitors, suggesting
that the compounds work by a mechanism that may affect either CodY synthesis or activity. CodY
activity would be reduced if the compounds caused the pools of branched chain amino acids or
GTP to drop (Dineen et al., 2007; Dineen et al., 2010). These data collectively suggest that the
antitoxigenic effect of CR and TC is mediated at least in part through CodY.
4. Conclusions
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To conclude, our study demonstrated that CR and TC were effective in significantly reducing
C. difficile toxin production. Although there were variations in the expression of toxin encoding
genes, both plant molecules reduced toxin production in all strains (BAA 1870, BAA1053,
BAA1805 and UK-1). The major toxin encoding genes, toxA, and toxB were significantly downregulated in all the tested strains by CR, whereas TC down-regulated these genes in all strains
except one (BAA 1805). Moreover, the two plant compounds at SIC concentrations did not inhibit
the growth of major gut microflora in humans. The anti-toxigenic effect of CR and TC appears to
be mediated through CodY. The results suggest the potential use of TC and CR to attenuate C.
difficile virulence; in vivo studies on the effect of CR and TC on CDAD are thus warranted.
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Figure 1. Effect of sub-inhibitory concentrations of carvacrol (CR) and transcinnamaldehyde (TC) on beneficial gut bacteria

Seven selected beneficial gut bacteria (Lactobacillus brevis (A), L. reuterii (B), L. delbrueckii
bulgaricus (C), L fermentum (D), L. plantarum (E), Bifidobacterium bifidum (F), and Lactococcus
lactis lactis (G)) were grown in de Man, Rogosa and Sharpe broth in anaerobic condition at 37 °C
with and without SICs of CR and TC (Control-Ctrl, open square, Carvacrol- CR, closed diamond,
trans-cinnamaldehyde-TC, open triangle) for 24 h. The bacterial growth was monitored by
measuring optical density at 600 nm measured at 6, 12 and 24 h. TC- or CR-treated gut bacterial
populations did not change significantly from the controls (p > 0.05).
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Figure 2. Effect of carvacrol (CR) and trans-cinnamaldehyde (TC) on C. difficile toxin
production. * p < 0.05 vs. CR.

Brain heart infusion with or without the Sub-inhibitory concentration (SIC) of TC or CR, (0.38
and 0.60 mM respectively) was inoculated (104 CFU/mL) separately with three hypervirulent C.
difficile isolates, ATCC BAA 1870 (A), ATCC BAA 1053 (B) or ATCC BAA 1805 (C), and
incubated anaerobically at 37 °C for 72 h. The culture supernatant from groups TC, CR and Control
(Ctrl) was collected at 15, 24, and 48 h of incubation for total toxin A and B quantitation by ELISA.
* Treatments significantly differed from the control (p < 0.05).
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Figure 3. Effect of carvacrol (CR) and trans-cinnamaldehyde (TC) on C. difficile induced
cytotoxicity on Vero cells.

Brain heart infusion with or without the Sub-inhibitory concentration (SIC) of TC or CR, (0.38
and 0.60 mM respectively) was inoculated (105 CFU/mL) separately with three hypervirulent C.
difficile isolates, ATCC BAA 1870 (A), ATCC BAA 1053 (B) or ATCC BAA 1805 (C), and
incubated anaerobically at 37 °C for 72 h. The culture supernatant from groups TC, CR and Control
(Ctrl) were collected at 15, 24, and 48 h of and the cytotoxicity titer on Vero cells was determined.
Serially diluted C. difficile culture supernatants were added to the monolayers in 96-well plates
and incubated at 37 °C under 5% CO2 for 48 h. The cell morphology was examined under an
inverted microscope for characteristic rounding as an indication of cytotoxicity.
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Figure 4. Effect of carvacrol (CR) on C. difficile toxin regulatory genes.

Brain heart infusion with or without the sub-inhibitory concentration (SIC) of CR, (0.60 mM) was
inoculated (105 CFU/mL) separately with three hyper virulent C. difficile isolates, ATCC BAA
1870 (A), ATCC BAA 1053 (B) or ATCC BAA 1805 (C), and incubated anaerobically at 37 °C
for 72 h. Bacterial pellets were harvested at 6 h and 12 h for RNA isolation and RT-qPCR for toxin
regulatory genes. * Treatments significantly differed from the controls at 24 and 48 h of incubation
(p < 0.05).
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Figure 5. Effect of trans-cinnamaldehyde (TC) on C. difficile toxin regulatory genes.

Brain heart infusion with or without the sub-inhibitory concentration (SIC) of TC, (0.38 mM) was
inoculated (105 CFU/mL) separately with three hyper virulent C. difficile isolates, ATCC BAA
1870 (A); ATCC BAA 1053 (B) or ATCC BAA 1805 (C), and incubated anaerobically at 37 °C
for 72 h. Bacterial pellets were harvested at 6 h and 12 h for RNA isolation and RT-qPCR for toxin
regulatory genes. * Treatments significantly differed from the controls at 24 and 48 h of incubation
(p < 0.05).
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Figure 6. Effect of carvacrol (CR) and trans-cinnamaldehyde (TC) on codY mutant and wild
type C. difficile toxin production.

Brain heart infusion with or without the sub-inhibitory concentration (SIC) of TC or CR, (0.38 and
0.60 mM respectively) was inoculated (105 CFU/mL) separately with UK1 and LB-CD16 (codY
mutant) C. difficile isolates, and incubated anaerobically at 37 °C for 24 h. The culture supernatants
from groups TC, CR and Control (Ctrl) were collected at 24 of incubation for total toxin A and B
quantitation by ELISA. * Treatments significantly differed from respective controls (p < 0.05).
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Figure 7. Effect of carvacrol (CR) and trans-cinnamaldehyde (TC) on codY mutant and wild
type C. difficile toxin genes.

Brain heart infusion with or without the sub-inhibitory concentration (SIC) of TC or CR, (0.38 and
0.60 mM respectively) was inoculated (105 CFU/mL) separately with wild type (wt) UK-1 and its
codY mutant (mt) C. difficile isolates, and incubated anaerobically at 37 °C for 72 h. Bacterial
pellets were harvested at 6 h and 12 h for RNA isolation and RT-qPCR for toxin regulatory genes.
* Treatments significantly differed from respective controls (p < 0.05).
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Chapter V
Effect of Carvacrol on Clostridium difficile sporulation and spore outgrowth
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Abstract
Clostridium difficile is an anaerobic spore-forming pathogen that causes a serious toxin-mediated
enteric disease in humans. Therapeutic agents that are capable of reducing C. difficile spore
production could significantly minimize the transmission and relapse of C. difficile infections. This
study investigated the ability of a food-grade, plant-derived compound, carvacrol (CR), to reduce
C. difficile spore production, germination and spore outgrowth. Two hyper-virulent C. difficile
isolates (ATCC BAA 1870 and 1805) were grown with or without the sub-inhibitory concentration
(SIC) of CR. Total viable counts and heat-resistant spore counts were determined at different time
intervals. Moreover, spores and vegetative cells were visualized using phase contrast microscopy.
For determining the effect of CR on C. difficile germination and spore outgrowth, C. difficile spores
were seeded in germination medium with or without the SIC and MIC of CR, and spore
germination and spore outgrowth were measured by recording optical density at 600 nm. The effect
of CR on C. difficile sporulation genes was also investigated using real-time qPCR. Carvacrol
significantly reduced sporulation in C. difficile and down-regulated critical genes involved in spore
production (P < 0.05). SIC or MIC of carvacrol did not inhibit C. difficile spore germination,
however, MIC of the phytochemical completely inhibited spore outgrowth. Results suggest that
CR could potentially be used to control the spread and relapse of difficile by reducing spore
production and outgrowth.
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Introduction
Clostridium difficile is a spore-forming, anaerobic bacterium that causes a toxin-mediated
enteric disease in humans (Weese, 2010). C. difficile predominantly affects long-term hospital
inpatients and the elderly undergoing prolonged antibiotic therapy (Hookman & Barkin, 2009).
Prolonged antibiotic therapy results in the disruption of the normal enteric microflora, causing C.
difficile spore germination and pathogen colonization in the intestine, with subsequent production
of toxins (Dial et al., 2005). Although toxins are the major virulence factors responsible for the
pathogenesis of C. difficile infection, spore formation, germination and spore outgrowth in C.
difficile are critical components of CDAD transmission and relapse (Deakin et al., 2012b). C.
difficile endospores can survive in the gut for a prolonged period of time (Paredes-Sabja et al.,
2014c). This leads to germination, proliferation and colonization of C. difficile in the gut following
prolonged antibiotic treatment that disrupts the normal gut flora, which in turn causes new
infections or relapse of CDAD (Riggs et al., 2007; Sun et al., 2011b). Relapse of CDAD is reported
in 25% of the patients undergoing anti-C. difficile therapy (Rupnik et al., 2009). Spore production
in C. difficile is regulated by several genes, including spo0A, which is the master regulator of
Spo0A, together with associated kinases and different sigma factors such as sigH (Rosenbusch et
al., 2012; Saujet et al., 2011; Underwood et al., 2009). Highly resistant C. difficile spores shed in
the faeces contaminate hospitals and healthcare facilities, which can cause infection through faecooral route or recurrence of CDAD in patients following germination and spore outgrowth (Barbut
et al., 2009; Hookman & Barkin, 2009).
Despite the fact that exposure to broad spectrum antibiotics predisposes patients to CDAD
by disrupting the normal gut flora (Bartlett, 1992; O'Connor et al., 2004), antibiotics still constitute
the chief treatment strategy against C. difficile. In addition, the emergence of antibiotic resistance
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in hypervirulent strains of C. difficile is documented (Prabaker & Weinstein, 2011; Spigaglia et
al., 2011). Therefore, alternative therapeutic agents that can attenuate C. difficile virulence without
disrupting the normal gut flora represent a viable control approach against the pathogen. Carvacrol
(CR) is a monoterpenoid phenol present in oregano and thyme oils. Various pharmacological
effects of CR, including antimicrobial and anti-inflammatory properties, have been demonstrated
(Baser, 2008). Our previous study indicated that CR effectively inhibited C. difficile toxin
production in vitro, without deleteriously affecting the major normal gastrointestinal flora in
humans (Mooyottu et al., 2014e). The objective of this study was to investigate the potential of
CR to inhibit spore production, spore germination and spore outgrowth in vitro, which are critical
in the spread and relapse of C. difficile infection, and to delineate the potential mechanism(s)
behind its effect.
2. Materials and methods
2.1 Bacterial strains and culture conditions
Two hypervirulent C. difficile isolates (ATCC BAA 1805, and 1870) were grown in brain
heart infusion broth (BHI) supplemented with 5% yeast extract (Difco, Sparks, MD, USA) in a
Whitley A35 anaerobic work station (Microbiology International, Frederick MD, USA) in the
presence of 80% nitrogen, 10% carbon dioxide and 10% hydrogen at 37oC for 24 h. The bacterial
population was determined by plating 0.1 ml portions of appropriate dilutions on BHI agar and
Clostridium difficile moxalactam norfloxacin (CDMN) agar (Oxoid, Lenexa, KS, USA)
supplemented with 5% horse blood, under strict anaerobic conditions at 37°C for 24 h. The cultures
were sedimented by centrifugation (3600 g, 15 min, 4°C), and the pellet was washed twice, and
resuspended in sterile phosphate-buffered saline (pH 7.3), and used as the inoculum.
2.2 C. difficile spore preparation
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C. difficile spores were prepared as previously described, with slight modifications (Sorg
& Dineen, 2009). Briefly, single colonies of ATCC BAA 1870 and 1805 were separately
inoculated into BHIS broth (BHI plus cysteine) and cultured overnight at 37°C under anaerobic
conditions. A volume of 150 µl aliquot of overnight culture was spread onto BHI agar (Oxoid) in
six well plates and cultured anaerobically for 10 days at 37°C in a Whitley A35 anaerobic
workstation to allow sporulation. After 10 days, spores were harvested from the wells by flooding
with 2 ml of ice cold sterile water. The spore suspension was heat-treated at 60°C for 20 min to
kill any vegetative cells, and washed six times in dH2O by centrifuging at 16,000 g for 5 min.
Spore suspensions were examined for purity by phase-contrast microscopy before storage at −20
°C prior to use.
2.3 Carvacrol and determination of SIC and MIC on C. difficile
The sub-inhibitory concentration (SIC) of CR (≥98% purity, Sigma Aldrich, St. Louis, MO,
USA) against C. difficile was determined, as previously described (Johny et al., 2010).
Approximately 5.0 log CFU C. difficile (ATCC BAA 1870 and 1805) was inoculated separately
in tissue culture plates containing 2 ml of BHI, followed by the addition of 1 to 10 μl of CR with
an increment of 0.5 μl. The plates were then incubated in an anaerobic chamber incubator at 37°C
for 24 h with 80% N2, 10% H2 and 10% CO2, and bacterial growth was monitored by determining
optical density at 600 nm (OD600). The lowest concentration of CR that inhibited bacterial growth
was selected as the MIC, and the two highest CR concentrations below the MIC that did not inhibit
bacterial growth after 24 h of incubation were selected as the SICs for this study.
2.4 Effect of CR on C. difficile growth and sporulation
The effect of CR on C. difficile growth and sporulation was determined according to a
previously published protocol (Babakhani et al., 2012). Briefly, BHI with or without the SICs of
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CR was inoculated (105 CFU/ml) separately with each C. difficile isolate, and incubated at 37oC
for 96 h anaerobically as before. Samples were withdrawn at different time intervals (24, 48, 72
and 96 h) for quantitation of heat-resistant spores (survivors of incubation at 60°C for 20 min) and
total viable count (TVC) by serially diluting each sample in PBS and plating on BHIS agar
supplemented with 0.1% taurocholate. In addition, sporulation in BHIS at the specified time
intervals was visualized under phase contrast microscopy (Burns et al., 2011). A 10 µL aliquot of
the culture from different treatment groups were loaded onto a microscopy slide, air-dried, and
visualised under 1.5×40x magnification.
2.5 Effect of SIC and MIC of CR on C. difficile spore germination and outgrowth
To study the effect of CR on C. difficile spore germination, 100 µl suspension containing
105 spores/ml was added to the wells of a 12-well plate containing 1.9 ml of pre-warmed, prereduced BHI supplemented with 0.1% sodium taurocholate (Sigma-Aldrich) inside an anaerobic
workstation. The plates were closed inside the workstation with lids and sealed with a sealant.
Brain heart infusion without taurocholate and spore suspensions or medium replaced with dH2O
were included as controls. A well with resazurin 0.1 mg/ml was included for examining
anaerobiosis in the plates during reading. Optical density at 600 nm was recorded using Synergy
plate reader (Biotek, Winooski, VT, USA) at 37°C over a 24 h time period, with readings taken at
10 min intervals, and was expressed as a percentage of the initial OD600 (t/t0). Spore germination
was measured as the initial loss of OD600 and spore outgrowth was measured by recording the
increase in OD600 followed by spore germination, as described previously (Allen et al., 2013;
Paredes-Sabja et al., 2008).
2.6. Real-time Quantitative PCR (RT-qPCR)
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To determine the effect of CR on C. difficile genes involved in spore production, total RNA
was isolated from early stationary phase cultures grown with and without the SIC of CR (Blossom
& McDonald, 2007). The culture supernatant was harvested by centrifugation at 3000 × g for 10
min at 4°C. The bacterial pellet was resuspended in RNAwiz solution (Ambion, Austin, TX, USA),
flash frozen in liquid nitrogen, and stored at −80°C. Total RNA extraction was performed using
the Ambion RiboPure Bacteria RNA kit (Ambion) according to the manufacturer's instructions,
followed by DNase I digestion using Turbo DNase I (Ambion). The RNA obtained after each
DNase I digestion was purified further using the Qiagen RNeasy RNA column purification kit
(Qiagen, Germantown, MD, USA). The cDNA was synthesized using the Bio-Rad iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA, USA). RT-qPCR analysis of the genes associated with spore
production was performed using published primers for genes associated with sporulation
(Babakhani et al., 2012; Saujet et al., 2011) and normalized against 16S rRNA gene expression.
Twenty-five μl reactions were performed in triplicate using iTaq SYBR (Bio-Rad, Hercules, CA,
USA). The relative fold change in gene expression was calculated using the 2-ΔΔCt method (Livak
& Schmittgen, 2001).
2.7 Statistical Analysis
All experiments had duplicate samples and the study was repeated three times. The data
were analyzed using the one-way ANOVA. Differences between means were considered
significantly different at p < 0.05.

3. Results
3.1 Sub-inhibitory concentrations of CR
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The MIC of CR against C. difficile was 1.2 mM. The two highest SICs of CR were found
to be 0.9 mM and 0.6 mM. These two concentrations of CR did not inhibit the growth of C. difficile
isolates after 24 h incubation at 37ºC.
3.2 Effect of CR on C. difficile growth and sporulation
The effect of SICs of CR on C. difficile spore production is shown in Fig. 1A and 1B. In
both C. difficile isolates, a significant decrease in spore counts was observed after 48 and 72 h of
incubation in CR-treated samples compared to control (p < 0.05)). In C. difficile BAA 1870, CR
at 0.6 mM and 0.9 mM resulted in ~ 1.5 log CFU/ml and 2.0 log CFU/ml reduction in spore counts
at 48 and 72 h of incubation, respectively. At 96 h, although spore counts in 0.6 mM CR-treated
samples grew back by ~ 1.0 log CFU/ml, CR treatment at 0.9 mM reduced the spore count ~ 3
logCFU/ml (Fig. 1A). However, differences in total viable counts (plated without heat treatment)
between CR-treated samples and untreated control were minimal (p > 0.05). Similar results were
also observed in C. difficile BAA 1805 (Fig. 1B), where ~ 1 log CFU/ml reduction in spore count
was observed in 0.6 mM CR treated cultures at 48, 72 and 96 h. Similarly, in the presence of 0.9
mM CR, a 2 log reduction in spore counts was observed consistently from 48 h through 96 h.
Moreover, the differences in total viable counts between CR-treated and control samples were less
than 1.0 log CFU/ml throughout the sampling times (p > 0.05). The results from the spoulation
experiments were consistent with phase contrast microscopy results of CR-treated and untreated
C. difficile cultures (Fig. 2). In untreated control, more phase bright spores and a fewer vegetative
bacteria populations were observed throughout the microscopic field. Conversely, in CR-treated
C. difficile culture, more number of vegetative bacteria and a lesser phase bright spores and a few
phase dark spores were observed after 48 h of incubation.
3.3 Effect of CR on C. difficile spore germination and outgrowth
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The effect of SIC (0.6 mM) and MIC (1.2 mM) of CR on C. difficile spore germination and
outgrowth over a 24 h time period was determined. In C. difficile BAA 1870, spore outgrowth was
observed in untreated wells, as indicated by an increase in OD600 starting at 11 h, with continued
increase over the 24 h duration (Fig. 3A). However, in the presence of 0.6 mM CR, C. difficile
spore outgrowth was delayed, as indicated by a lower absorbance at each sampling time point (p
< 0.05). In addition, the MIC of CR (1.2 mM) completely inhibited spore outgrowth, as evident
from a lack of increase in absorbance at 600 nm. In C. difficile BAA 1805, CR was found more
effective, where at 0.6 mM spore outgrowth was delayed by 3h and the growth was found to be
decreased throughout the sampling points (p > 0.05) (Fig. 3B). Moreover, CR at 1.2 mM
completely shut down spore outgrowth as observed with C. difficile BAA 1870. No significant
difference was observed in the initial dip in the OD600 in both CR treated (SIC and MIC) and
untreated C. difficile, indicating that, neither SIC nor MIC of CR was able to reduce C. difficile
spore germination.
3.4 Effect of CR on C. difficile spore production genes
To investigate if the observed reduction in C. difficile spore production was due to a
modulation in the expression of genes known to be involved in sporulation, RT-qPCR was
performed. The results showed that CR significantly down-regulated the transcription of C.
difficile sporulation genes, where the expression of spo0A was down-regulated by 22 folds in BAA
1870 and 13 folds in BAA 1805, and that of spoIIA by 23 and 25 folds in BAA 1870 and BAA
1805, respectively. (Fig. 4A and 4B).In addition, the transcription of spoIIR was decreased by 7
and 8 folds and that of spoIIID by 5 and 7 folds in C. difficile BAA 1870 and 1805, respectively
(p < 0.05). Similarly, sigH was down-regulated by 19 and 26 folds in C. difficile BAA 1870 and
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BAA 1805,s respectively (p < 0.05). Likewise, the expression of CD2492 was also reduced by 14
and 7 folds in C. difficile BAA 1870 and BAA 1805 isolates, respectively (p < 0.05).
4. Discussion
C. difficile is a major nosocomial pathogen, and recent epidemiologic data have shown that
C. difficile has surpassed methicillin-resistant Staphylococcus aureus as the most commonly
acquired hospital infection (Miller et al., 2010). Sporulation is a critical virulence factor in C.
difficile pathogenesis. C. difficile spores being survival structures that can withstand unfavorable
physical, chemical and metabolic conditions, play an important role in bacterial persistence in the
environment, transmission to new susceptible individuals and relapse in temporarily recovered
patients (Paredes-Sabja et al., 2014c). C. difficile spores enter the host by feco-oral route,
germinate in the presence of bile acid in the small intestine and colonize the colon, where
vegetative cells produce toxins, leading to severe diarrhea (Hookman & Barkin, 2009). Further,
sporulation of vegetative cells occurs in the colon, and newly formed spores shed in the feces can
potentially contaminate hospitals and healthcare facilities leading to new infections (Simor et al.,
2002). Therefore, agents reducing C. difficile sporulation and spore outgrowth in the human
gastrointestinal tract could effectively control C. difficile infection, transmission, and relapse
(Johnson, 2009; Maroo & Lamont, 2006). Results from this study suggest that CR, a plant-derived,
food-grade compound which has been previously shown to exert anti-toxigenic effect in C. difficile
can significantly reduce C. difficile spore production and spore outgrowth in vitro.
Results from this study demonstrate that the SICs of CR significantly reduced spore
production by C. difficile at 48, 72 and 96 h of incubation (p < 0.05). The reduction in sporulation
in CR-treated samples was determined by dilution and plating method, and also visualized using
phase contrast microscopy. Interestingly, no reduction in total number of viable cells (TVC, which
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constitute both vegetative cells and spores) was observed in CR-treated C. difficile cultures
compared to untreated control. These results indicate that CR was able to specifically inhibit the
formation of spores from the vegetative cells in broth culture. A slight increase in TVC of CRtreated cultures could be due to the presence of higher proportion of vegetative cells, which have
superior detection limit on plating compared to spores. Since the SICs of CR were used in the
sporulation experiments, the decrease observed in C. difficile spore production in CR-treated
samples was not due to inhibition of bacterial growth by CR, but could be attributed to their
potential ability to reduce the transcription of virulence genes associated with spore production.
Concurring this, the gene expression studies indicated that CR significantly down-regulated
critical genes responsible for C. difficile sporulation. In the germination experiments, the results
revealed that the SIC of CR (0.6 mM) significantly reduced C. difficile spore outgrowth (outgrowth
of vegetative cells from the newly germinated spores) compared to controls (p < 0.05), whereas
CR at the MIC (1.2 mM) completely inhibited the spore outgrowth. These results suggest that
vegetative cells from newly germinated spores are more sensitive to CR compared to vegetative
C. difficile cells grown in broth.
A potential alternate strategy for controlling microbial infections is the use of antivirulence drugs, which target reducing bacterial virulence rather than inhibiting bacterial growth
(Rasko & Sperandio, 2010), thereby presenting a lesser selective pressure for development of
bacterial antimicrobial resistance (Cegelski et al., 2008; Hughes & Sperandio, 2008; Hung et al.,
2005). The results of the current study indicate that CR inhibited sporulation in C. difficile, which
aids in bacterial virulence especially towards CDAD transmission and relapse. Moreover, prior
research conducted in our laboratory revealed that SICs of CR inhibited the production of C.
difficile toxins, which represent another important virulence factor in the pathogen without
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inhibiting the normal hut bacteria (Mooyottu et al., 2014b). Research by others have also reported
that CR exerted no adverse effects on endogenous bacterial populations, including Lactobacilli
and Bifidobacteria in pigs and poultry (Jamroz et al., 2005). To conclude, the results from this
study suggest the potential of CR for controlling C. difficile by reducing spore production and
outgrowth, thereby warrants follow-up in vivo studies to confirm the findings.
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Figures
Fig. 1 Effect of carvacrol (CR) on C. difficile BAA 1870 (1A) and 1805 (1B) growth and
sporulation
Brain heart infusion with or without the Sub-inhibitory concentrations (SIC) of CR, (0.6 mM and
0.9 mM) was inoculated (105 CFU/ml) separately with C. difficile BAA 1870 (A) and BAA 1805
(B), and incubated anaerobically at 37oC for 96 h. Samples were withdrawn at different times for
quantitation of heat-resistant spores (survivors of incubation at 60°C for 20 minutes) and total
viable count (TVC) by serially diluting each sample in PBS and plating each in duplicate on BHIS
agar supplemented with 0.1% taurocholate. * Treatments significantly differed from the respective
controls (p<0.05)
1A
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Fig. 2: Effect of carvacrol (CR) on C. difficile ATCC BAA 1870 and BAA 1805 sporulation.
Brain heart infusion with or without the Sub-inhibitory concentration (SIC) of CR, (0.6 mM) was
inoculated (105 CFU/ml) separately with C. difficile BAA 1870 and BAA 1805, and incubated
anaerobically at 37oC for 96 h, Sporulation at 48 h of incubation in BHIS was visualized under
phase contrast microscopy. A 10µl aliquot of the culture from different treatment groups were
loaded onto a microscopy slide, air dried, and visualised at 1.5×40x magnification. A) Control C.
difficile BAA 1870 B) C. difficile BAA 1870 with 6mM CR, C) Control C. difficile BAA 1805,
D) C. difficile BAA 1805 with 6mM CR.
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Fig. 3: Effect of carvacrol (CR) on germination and outgrowth of C. difficile BAA 1870 (3A)
and 1805 (3B) spores.
Spore suspension containing 105 spores/ml was added to the wells of a 12-well plate containing
1.9 ml of pre-warmed, pre-reduced BHI supplemented with 0.1% sodium taurocholate was
incubated with 0mM, 6mM or 12Mm CR inside an anaerobic workstation. The plates were closed
inside the workstation with lids and sealed with a sealant. BHI media without taurocholate, and
spore suspensions or culture media replaced with dH2O were included as controls. A well with
resazurin 0.1 mg/ml was included for examining anaerobiasis in 12 well plate during reading.
Optical density at 600 nm (OD600) were recorded using Synergy plate reader at 37 °C over a 24
h time period with readings taken at 10 min intervals and was expressed as a percentage of the
initial OD600 (t/t0). Germination was measured as the initial loss of OD600 and Spore outgrowth
was measured by recording the increase in OD600 followed by spore germination.
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Fig. 4: Effect of carvacrol (CR) on C. difficile ATCC BAA 1870 (4A) and 1805 (4B) toxin
regulatory genes.
Brain heart infusion with or without the sub-inhibitory concentration (SIC) of CR, (0.6 mM) was
inoculated (105 CFU/ml) separately with C. difficile isolates, BAA 1870 (A), BAA or BAA 1805
(B), and incubated anaerobically at 37oC for 72 h. Bacterial pellet was harvested at 12 h for RNA
isolation and RT-qPCR for spore production genes. * Treatments significantly differed from the
controls at 24 and 48 h of incubation (p<0.05).
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Chapter VI
Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated
Disease in a Mouse Model
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Abstract
Clostridium difficile is an anaerobic sporeforming pathogen causing a toxin-mediated
enteric disease in humans. C. difficile predominantly affects hospital inpatients undergoing
prolonged antibiotic therapy, which results in enteric dysbiosis, leading to C. difficile spore
germination, pathogen colonization in the intestine and subsequent toxin production. Therapeutic
agents that inhibit C. difficile without causing enteric dysbiosis could improve the clinical outcome
of C. difficile infections. Our previous studies indicated that carvacrol (CR), a plant-derived
compound significantly inhibited C. difficile toxin production and spore outgrowth in vitro. This
study investigated the effect of CR on antibiotic-associated gut dysbiosis and C. difficile infection
in a mouse model.
Five to six-week-old C57BL/6 mice were randomly divided into seven treatment groups
(challenge and control) of eight mice each. Mice were fed with irradiated feed supplemented with
CR (0%, 0.05%, and 0.1%); the challenge groups were made susceptible to C. difficile by orally
administering an antibiotic cocktail in water and an intra-peritoneal injection of clindamycin. Both
challenge and control groups were infected with 105 CFU/ml of hypervirulent C. difficile (ATCC
1870) spores or PBS, and observed for clinical signs for ten days. Respective control groups for
CR, antibiotics, and their combination were included for investigating their effect on mouse enteric
microflora. Mouse body weight and clinical and diarrhea scores were recorded daily post infection.
Fecal samples were collected for microbiome analysis using rRNA sequencing in MiSeq platform.
Carvacrol supplementation significantly reduced the incidence of diarrhea and improved
the clinical and diarrhea scores in mice (p<0.05). Microbiome analysis revealed a significant
increase in Proteobacteria and reduction in the abundance of protective bacterial flora in antibiotictreated and C. difficile-infected mice compared to controls (p<0.05). However, CR
158

supplementation positively altered the microbiome composition, as revealed by an increased
abundance of beneficial bacteria, including Firmicutes, and significantly reduced the proportion
of detrimental flora such as Proteobacteria, without significantly affecting the gut microbiome
diversity compared to control. Results suggest that CR could potentially be used to control gut
dysbiosis and reduce C. difficile infection.
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1. Introduction
Clostridium difficile infection is the major cause of antibiotic-associated diarrhea in
hospital settings around the world (Hookman & Barkin, 2009; McFarland, 2008). C. difficile
principally causes a serious toxin-mediated colitis in the elderly and immunocompromised patients
(Weese, 2010). Annually, more than 300,000 cases of C. difficile associated diseases (CDAD) are
reported in the United States, resulting in more than US$3 billion as health care costs (Ghose et
al., 2007; Wilkins & Lyerly, 2003). A recently emerged, highly toxigenic and hyper-virulent C.
difficile strain NAP1/ribotype 027 has been implicated in increasing incidence of CDAD among
patients all over the world (Blossom & McDonald, 2007; Hookman & Barkin, 2009; Sunenshine
& McDonald, 2006).
C. difficile infection has been associated with the use of antibiotics and gastric acid
suppressing agents that result in gut dysbiosis (Bartlett, 1992; Dial et al., 2005; Kelly & LaMont,
1998). Prolonged antibiotic therapy results in the disruption of the normal enteric microflora,
leading to an altered microbial composition such as increased population of Proteobacteria and
reduced proportion of Bacteroides and Firmicutes in the gut microbiome (Ling et al., 2014; Seekatz
& Young, 2014; Shahinas et al., 2012; Theriot et al., 2014). Consequently, gut dysbiosis results in
the germination of spores and selection for C. difficile in the intestine. Following spore germination
and outgrowth in the presence of a disrupted gut flora, the vegetative cells of C. difficile produce
potent toxins known as toxin A and toxin B (Voth & Ballard, 2005). Clostridium difficile toxins
(A and B) are functionally glucosyl transferases, which inactivate the Rho family GTPases
associated with F-actin regulation, and cause disruption of the cytoskeleton and intestinal epithelial
tight junctions (Keel & Songer, 2006; von Eichel-Streiber et al., 1999). This leads to a severe
inflammatory response with the release of cytokines and leukotrienes, causing pseudomembrane
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formation and severe diarrhea (Hookman & Barkin, 2009; McDonald et al., 2006; Sunenshine &
McDonald, 2006). Since gut dysbiosis is considered as the most important predisposing factor in
CDAD, emerging and novel therapeutic approaches, including fecal microbiome transplantation
(FMT) primarily aimed at restoration of the normal gut flora in CDAD patients are explored
(Kassam et al., 2013).
Despite the fact that a majority of the currently used antibiotics can predispose CDAD by
disrupting the normal gut flora, antibiotics are still used as the primary line of treatment against
infection (Bartlett, 1992; O'Connor et al., 2004). Nonetheless, many of the anti- C. difficile
antibiotics are found to predispose CDAD in patients by inducing gut dysbiosis (McFarland, 2008;
O'Connor et al., 2004; Shah et al., 2010). Moreover, the emergence of antibiotic resistant strains
of hypervirulent C. difficile is documented worldwide (Spigaglia et al., 2011; Steiner et al., 2012).
The Centers for Disease Control and Prevention (CDC) recently listed C. difficile as one among
the three urgent threats in their report on emerging pathogens with antibiotic resistance (Steiner et
al., 2012). Since the toxins are the major virulence factors for CDAD, a search for alternative
therapeutic agents, which can reduce C. difficile virulence without affecting normal
gastrointestinal flora opens a new research area.
Carvacrol (CR) is a food grade, monoterpenoid phytophenol that is naturally present in
oregano and thyme oil. Diverse pharmacological actions of carvacrol, including antimicrobial and
anti-inflammatory activities have been previously demonstrated (Baser, 2008). A recent study
from our laboratory suggested the potential use of CR as an anti-C. difficile therapeutic agent due
to its inhibitory effect on C. difficile toxin production without affecting the growth of beneficial
gut bacteria in vitro (Mooyottu et al., 2014c). This study demonstrated that CR significantly
inhibited toxin production in hypervirulent C. difficile strains by modulating toxin production
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genes. Therefore, this study investigated the therapeutic effect of CR against C. difficile in an in
vivo model, specifically its impact on the clinical course of C. difficile infection and the host
microbiome. Mouse is a well-established model of C. difficile infection (Chen et al., 2008; Sun et
al., 2011a), and antibiotic-associated C. difficile infection can be induced in a mouse model by
administering antibiotics orally and intraperitoneally, followed by inoculation of C. difficile spores
(Chen et al., 2008; Sun et al., 2011a).
2. Materials and methods
2.1 Ethics statement, animals, and housing
This study was conducted with the approval of the Institutional Animal Care and Use
Committee (IACUC) of the University of Connecticut. All recommended guidelines for the care
and use of animals were followed. Six-week-old C57BL/6 mice were obtained from Charles River
(Boston, MA). Animals were housed in a biohazard level II, AALAC-accredited facility and
monitored twice daily for health. Mice were provided with autoclaved food, water, and bedding,
with 12-h light/dark cycles. All cage changes, C. difficile spore infection, and sample collections
were performed under a laminar flow hood using properpersonal protective equipment. The work
area was sterilized using 10% bleach between experimental treatment groups to prevent crosscontamination. The mice were housed in pairs in a cage, and four cages were included for each
treatment in each of the experiments.
2.2 Mouse model of C. difficile infection and treatment groups
The infection model adopted for this study is a modification of the method described by
Chen et al. (2008). Five to six-week-old female mice were randomly divided into eight treatment
groups of eight animals each (Table 1). The animals were subjected to food restriction for 12 h,
and given powdered feed supplemented with 0, 0.05 and 0.10% of CR. After 7 days, an antibiotic
162

mixture was added in drinking water (kanamycin,0.4 mg/mL, gentamicin,0.03 mg/mL,
colistin,850 U/mL, metronidazole, 0.215 mg/mL, and vancomycin,0.045 mg/mL) for 3 days. After
the antibiotic treatment, all mice were given regular autoclaved water for two days, and all animals,
including the control group received a single dose of clindamycin (10 mg/kg, maximum volume
of injection 0.5 ml/mouse using a 27 gauge gavage needle and syringe) intraperitoneally one day
before C difficile challenge. This antibiotic pre-treatment was intended to disrupt the normal gut
flora of mice and facilitate C. difficile colonization. All animals were infected by oral gavage with
105 colony-forming units (CFU) per 0.1 ml total volume of hypervirulent C. difficile spores (ATCC
BAA 1805) using a straight 18-gauge needle with 1” shaft length, and were monitored for signs of
CDAD such as diarrhea, hunched posture and wet tail using a mouse clinical score sheet (Tables
1 & 2). Animals were observed twice daily for ten days for mortality and morbidity. The individual
weight of each animal was measured every day. Fecal samples from all animals were collected on
alternate days post infection. The animals were euthanized at the end of the experiment (10th day
after C. difficile challenge).
2.3 DNA extraction, PCR amplification, and sequencing of taxonomic marker:
DNA was extracted from 0.25g of fecal sample (collected on the 2nd day post inoculation,
DPI) from all treatment groups using the MoBio PowerMag Soil 96 well kit (MoBio Laboratories,
Inc), according to the manufacturer’s protocol for the Eppendorf ep Motion liquid handling robot.
DNAquantification was performed using the Quant-iT PicoGreen kit (Invitrogen, ThermoFisher
Scientific). Partial bacterial 16S rRNA genes (V4) were amplified using 30 ng extracted DNA as
template. The V4 region was amplified using 515F and 806R with Illumina adapters and dual
indices (8 basepair golay on 3’; Caporaso, 2012), and eight basepair on the 5’ (Kozich, 2013).
Samples were amplified in triplicate using Phusion High-Fidelity PCR master mix (New England
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BioLabs) with the addition of 10 µg BSA (New England BioLabs). The PCR reaction was
incubated at 95˚C for 3.5 minutes, then 30 cycles of 30 s at 95.0°C, 30 s at 50.0°C and 90 s at
72.0°C, followed by a final extension at 72.0°C for 10 minutes were used. The PCR products were
pooled for quantification and visualization using the QIAxcel DNA Fast Analysis (Qiagen). The
PCR products were normalized based on the concentration of DNA from 250-400 bp and pooled
using the QIAgility liquid handling robot. The pooled PCR products were cleaned using the Gene
Read Size Selection kit (Qiagen) according to the manufacturer’s protocol. The cleaned pool was
sequenced on MiSeq using v2 2x250 base pair kit (Illumina, Inc).
2.4 Sequence Analysis
The microbiome analysis was set up as a completely randomized design with treatments
done in replicates of six. The sequences were filtered and clustered using Mothur 1.36.1 based on
a published protocol with slight modifications (Kozich et al., 2013). Operational taxonomic units
(OTUs) were clustered at 97% sequence similarity. Downstream analysis of samples was done
using R version 3.2. The alpha diversity was calculated using inverse Simpson to measure the
richness and evenness of the OTUs. The effect of treatment on the alpha diversity was analyzed
using Tukey’s Test. A permutational multivariate analysis (PERMANOVA, adonis function, 75
permutations) was conducted to analyze the effect of various treatments on the bacterial
community composition. Significant change in alpha diversity was determined by Anova followed
by Tukey’s honest significant differences adjusting for multiple comparisons (p-value=0.05).
NMS ordinations were run in R (v 3.3.0) using metaMDS in the vegan (v 2.3-5) package after
calculating the stress scree plots to determine the number of axes required to achieve stress below
0.2, plotted using ggplot2 (v 2.1.0). Finally, the relative abundance of OTUs of major phyla, order,
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and genera was determined to assess the effect of treatment. Tukey’s Test was used to identify
changes in groups of bacteria based on treatment and the significance was detected at P < 0.05.
2.5 Statistical analysis
The results were expressed as means ± standard errors of the means (SEM). The differences
between the experimental groups were compared using the analysis of variance (ANOVA). Twoway ANOVA was used to compare experimental groups across the days. The differences between
two groups were analyzed using unpaired Student's t-test. The statistical significance level was set
at a P value of <0.05.
3. Results
3.1 Effect of CR supplementation on the incidence of diarrhea and severity of C. difficile
infection in mice
In order to assess the prophylactic effect of CR against C. difficile associated diarrhea in
mice, the animal diets were supplemented with CR at two different concentrations (0.05% and
0.1%) in feed prior to antibiotic treatment and subsequent C. difficile infection (Ant + CD + 0.05%
CR and Ant + CD + 0.1% CRThe oral administration of 105 CFU/ml NAP1 C. difficile spores
resulted in high morbidity and low mortality in infected mice. In C. difficile infected control groups
(Ant+CD), 75% of the animals showed severe diarrhea on 1DPI, and 90% of the animals showed
severe diarrhea on 2DPI. Two animals died on 1DPI, and no further mortality was observed in this
group. No increase in the incidence of diarrhea was observed after 2DPI (Fig. 1). Interestingly,
only 50% of the animals showed diarrhea in 1DPI in Ant + CD + 0.05% CR group (animals
supplemented with 0.05% CR prior to the antibiotic treatment and subsequent C. difficile
infection), no increase in the incidence of diarrhea was reported after 1DPI. In Ant + CD + 0.1%
CR group, only 10% of the animals showed diarrhea on 1DPI, which further increased to 25% on
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2DPI and no further incidents were observed on subsequent days. In both CR-treated and C.
difficile infected groups (Ant + CD + 0.05% CR and Ant + CD + 0.1% CR), two mortalities each
were recorded on 2DPI. No diarrheal symptoms were observed in control groups (Negative
control, CR control, Ant control and Ant+CR control).
3.2 Effect of CR supplementation on clinical score and body weight of C. difficile infected
mice
Clinical scores of the individual animals in different groups were recorded using standard
clinical score chart, from 1DPI to 7 DPI (Table. 2a and 2b) (Chen et al., 2008; Sun et al., 2011a).
The C. difficile control group (Ant+CD group) exhibited significantly increased severity, as
indicated by a higher average clinical score per group on 1, 2, 3 and 4 DPI (p<0.05). The severity
of CDAD in animals supplemented prophylactically with 0.05% and 0.1% CR (Ant + CD + 0.05%
CR and Ant + CD + 0.1% CR groups) was lesser than that of the untreated group (Ant+CD)
(p<0.05). On 1DPI, there was a dose-dependent reduction in the severity of infection in CR
supplemented groups. Irrespective of the treatments, all surviving morbid animals recovered by
6DPI, as indicated by a zero clinical score.
A similar trend was observed in average body weights of animals in different treatment
groups. Body weights were recorded daily and the relative percentage weight with respect to the
initial weight before C. difficile infection was calculated (Fig. 3). Carvacrol alone (CR control) and
in combination with antibiotic (Ant+CR control) did not cause any significant weight loss
compared to the negative control. All mice in the C. difficile control group (Ant+CD) showed
significant and progressive weight loss from 1 DPI to 5DPI compared to the negative control
(p<0.05). However, CR-treated and C. difficile infected mice (Ant + CD + 0.05% CR and Ant +
CD + 0.1% CR groups) showed a significantly lesser weight loss in comparison to untreated and
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C. difficile infected group (Ant+CD) from 1 DPI and 2DPI, with regaining of the initial weight on
3DPI (p<0.05). No significant difference in recorded weight loss was observed between 0.05 and
0.1% CR-treated C. difficile infected mice except for a rapid and early increase in the body weight
on 2DPI in the 0.05% CR group.
3.3 Effect of CR supplementation on the gut microbiome of C. difficile infected and noninfected mice.
Microbiome analysis results revealed specific patterns in the composition of different
bacterial taxa in different treatment groups. In the phylum level, the gut microbiome of negative
control mice was predominated by Bacteriodetes, followed by Firmicutes (Fig. 4) with a minimal
proportion of other phyla, including Proteobacteria. A similar trend was observed in CR control
group, with an abundance of Bacteriodetes followed by Firmicutes, although the proportion of
Firmicutes was slightly higher than that of the negative control group. Antibiotic administration
significantly increased the proportion of Proteobacteria in antibiotic-treated (Ant control) group
compared to the negative control and CR control groups (p<0.05). Interestingly, supplementation
of CR along with antibiotic (Ant + CR control) significantly reduced the abundance of
Proteobacteria compared to the antibiotic only (Ant control) group. The C. difficile control group
(Ant + CD), where C. difficile spores were orally gavaged after antibiotic treatment, exhibited a
remarkably increased abundance of Proteobacteria along with a greater proportion of
Verrucomicrobia compared to all other control groups (Negative control, CR control, Ant control,
Ant+ CR control groups) (p<0.05). In addition, the abundance of Bacteriodetes and Firmicutes
was significantly reduced in C. difficle control group (Ant+CD), compared to uninfected controls
(p<0.05). Strikingly, this alteration in the abundance of Proteobacteria, Firmicutes, Bacteriodetes
and Verrucobacteria due to C. difficile infection was reversed significantly by CR
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supplementation, as observed in the CR-treated and C. difficile infected groups (Ant + CD + 0.05%
CR and Ant + CD + 0.10% CR groups) (p<0.05).
At the Order and Family level, an increased abundance of Enterobacteriaceae was observed
in antibiotic alone (Ant control) and C. difficile (Ant+CD) groups compared to negative control
and CR control groups (Fig. 5a). Moreover, CR supplementation significantly reduced the
abundance of Enterobacteriaceae induced by the antibiotic administration and C. difficile infection,
as indicated by a significant reduction in their abundance in Ant + CR control group, Ant + CD +
0.05% CR and Ant + CD + 0.10% CR groups (p<0.05) (Fig. 5a). Carvacrol treatment significantly
increased the abundance of Lactobacillaceae and Lachnospiraceae in the gut microbiome
compared to that of negative control (Fig. 5b) (p<0.05). The abundance of Lactobacillaceae and
Lachnospiraceae was significantly reduced following antibiotic treatment (Ant control group) and
C. difficile (Ant+CD control group) infection, compared to the Negative control and CR alone (CR
control) groups (p<0.05). This effect was significantly reversed by the supplementation of CR in
Ant + CR control, Ant + CD + 0.5 CR and Ant + CD + 0.5 CR groups.
Inverse Simpson plot revealed a differential pattern of bacterial diversity in various
treatment groups (Fig. 6). Strikingly, CR treatment did not alter the diversity of the gut bacterial
community compared to the untreated control group (Negative control). As expected, antibiotic
treatment significantly reduced the bacterial diversity compared to control and CR group. There
was a marked reduction in the diversity of the bacterial community in C. difficile infected groups,
irrespective of the CR treatment. Moreover, NMDS plot representing the relationships between
samples in various treatment groups based on the abundance of species present in each sample
revealed a close clustering of CR control samples and untreated control samples (Fig. 7). This
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representation suggests that the species abundance in CR treatment groups is comparable to
untreated mice indicating minimal effect of CR on gut microbial diversity.
4. Discussion
Prolonged antibiotic therapy and subsequent gut dysbiosis result in C. difficile spore
germination, and colonization of the large intestine with vegetative cells of the bacterium, and
subsequent production of toxins TcdA and TcdB, resulting in C. difficile associated diarrhea [1].
C. difficile toxins lead to intestinal inflammation, increased epithelial permeability (Castagliuolo
et al., 1998; Feltis et al., 2000; He et al., 2002), enhanced cytokine and chemokine production
(Castagliuolo et al., 1998; He et al., 2002), neutrophil infiltration (Kelly et al., 1994) and the release
of reactive oxygen intermediates (He et al., 2002), thereby causing direct damage to the intestinal
mucosa (Ng et al., 2010). Antibiotics are the primary line of treatment in C. difficile infection,
although the use of antibiotics has been documented for inducing and aggravating gut dysbiosis
and relapse of the infection post-therapy. In addition, increasing incidence of C. difficile acquiring
antibiotic resistance is reported worldwide.
In the current study, we investigated the prophylactic efficacy of CR as an alternative
antimicrobial agent that can ameliorate C. difficile associated diarrhea without inducing gut
dysbiosis. Previous studies have reported that supplementation of low doses of CR exerted no
detrimental effects on endogenous bacterial populations, including Lactobacilli and Bifidobacteria
in pigs and poultry (Jamroz et al., 2005; Si et al., 2006).
Previous studies conducted in our laboratory revealed that SICs of CR reduced C. difficile
toxin production and cytotoxicity in Vero cells in vitro (Mooyottu et al., 2014d). In addition, our
previous experiments showed an inhibition of C. difficile spore outgrowth in the presence of CR
(Mooyottu et al., 2014a). The results from the mice experiment indicated that our in vitro results
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apparently well translated in vivo with regards to the clinical outcome and gut microbiome of the
animals when prophylactically treated with CR prior to C. difficile infection. As expected, CR
supplementation significantly reduced the incidence of diarrhea in C. difficile infected mice (p <
0.05). Moreover, CR supplementation significantly reduced the severity of clinical infection in C.
difficile infected mice, as evident from a reduced average clinical score compared to the infected
control group (Ant+CD) (p < 0.05). However, CR-treated and C. difficile infected mice exhibited
significantly lesser weight loss compared to the untreated group (Ant+CD). The reduced severity
of CDAD in CR-treated mice compared to infected control group (Ant+CD) could be attributed to
an inhibitory effect of the phytochemical on C. difficile spore outgrowth and/or the toxin
production, as observed in our in vitro studies. Moreover, CR has been reported to possess antiinflammatory and anti-diarrheal properties (Baser, 2008), which could also have exerted a
beneficial effect in C. difficile infected mice.
A healthy and normal gut microflora is crucial for preventing pathogen colonization and a
variety of enteric bacterial infections, including C. difficile (Britton & Young, 2014). The most
important predisposing factor for C. difficile infection is the disruption of normal gut microbiota
(Hookman & Barkin, 2009). Antibiotic therapy significantly alters the microbial composition and
diversity; and in many cases alterations in the microbial diversity persist to an extent, even after
withdrawing antibiotic administration (Antonopoulos et al., 2009; Dethlefsen et al., 2008b). In
human patients, as age advances, the protective bacterial population of Firmicutes considerably
diminishes accompanied by an increase in Bacteroidetes and undesirable species of Proteobacteria
in the gut (Biagi et al., 2010; Claesson et al., 2011; Hopkins et al., 2001b). Moreover, age-related
senescence in the immune status of the elderly, along with frequent hospital visits during old age
contribute to a detrimental alteration in the gut microbiome and subsequent colonization of C.
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difficile (Seekatz & Young, 2014). Other important factors that detrimentally affect the gut
microbiota and predispose C. difficile infection are the use of proton pump inhibitors and chronic
gastrointestinal diseases (Berg et al., 2013; Dial et al., 2005; Vesper et al., 2009). Proton pump
inhibitors alter the pH of the gut, thereby affecting the microbial population, especially beneficial
bacteria such as Lactobacillus species (Altman et al., 2008; Vesper et al., 2009). In addition,
disease conditions such as inflammatory bowel disease (IBD) induce significant gut dysbiosis,
which reduces the diversity of the protective population of Firmicutes and Bacteroides population
accompanied by an increased Proteobacteria in the gut of affected patients (Manichanh et al., 2006;
Nagalingam & Lynch, 2012). Increased abundance of Verrucomicrobia has also been shown in
patients with antibiotic-associated gut dysbiosis (Weingarden et al., 2014). Moreover, the paucity
of Firmicutes, especially the depletion of Ruminococcaceae, Lachnospiraceae, and butyrogenic
bacteria within this phylum observed in C. difficile infection and nosocomial diarrhea in humans
(Antharam et al., 2013). Moreover, C. difficile infected patients have a higher count of
Enterobacteriaceae (Proteobacteria) and decreased Enterococcaceae (Firmicutes) (Hopkins &
Macfarlane, 2002; Rea et al., 2012; Schubert et al., 2014).
The changes in the gut microbiome diversity and alterations in the relative abundance of
different bacterial communities in human patients are replicated in mice models of C. difficile
infection (Semenyuk et al., 2015). Antibiotic treatment and subsequent C. difficile infection
significantly reduced the abundance of Firmicutes and Bacteroides in phylum level. Similar trends
are observed in all taxonomical level such as a reduction in protective Lactobacillaceae,
Lachnospiracea, and Bifidobacteriacea. A dramatic increase in the abundance of Proteobacteria
specifically Enterobacteriaceae has been found in the antibiotic treated and C. difficile infected
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mice(Semenyuk et al., 2015). Similarly, antibiotic treatment and subsequent C. difficile infection
significantly reduced microbiome diversity in mouse gut (Semenyuk et al., 2015).
In this study, CR treatment did not reduce the bacterial diversity in the mouse gut. To date,
a majority of the antimicrobial compounds, especially antibiotics, have significantly altered the
microbial diversity, and cause dysbiosis by changing the abundance of bacterial communities
(Semenyuk et al., 2015). Moreover, CR treatment significantly increased the abundance of
beneficial bacterial populations such as Firmicutes, specifically the members of Lactobacillaceae
and Lachnospiraceae. In addition, CR treatment alone did not increase the abundance of
detrimental bacterial populations compared to untreated control animals. Strikingly, CR reduced
antibiotic-induced increases in the abundance of unfavorable bacterial populations such as
Proteobacteria, specifically pathogenic gamma proteobacteria, including Enterobacteriaceae and
other bacterial populations such as Verrucobacteria (Fig. 5a). Surprisingly, this beneficial shift
brought about by CR treatment in the gut microbiome of antibiotic-treated and C. difficile infected
animals is very much similar to that of human patients who have undergone fecal microbiome
transplantation (Weingarden et al., 2014), which is documented as one of the most effective
strategies against severe C. difficile infection (Ofosu, 2016b; Schenck et al., 2015). These results
suggest that reduced or delayed clinical infection rate and less severe clinical presentation of CRtreated animals could attributed in part to the beneficial shift in the gut microbiome.
To conclude, our results suggest CR supplementation to be protective against C. difficile
infection in mice. Carvacrol supplementation significantly reduced the incidence of diarrhea and
mitigated the severity of C. difficile induced clinical symptoms, inducing a favorable shift in the
composition of the gut microbiota without detrimentally affecting the gut microbiome diversity in
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mice. These findings suggest the potential of CR as an anti- C. difficile agent, however, further
clinical studies are warranted to confirm this.
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Table 1. Different treatment groups used in the experiment:

Abbreviations: Ant (Antibiotic), CD (C. difficile), CR (Carvacrol)
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Table 2a. Mouse clinical score sheet:
MOUSE CLINICAL SCORE SHEET

Coat

0

1

3

Normal

Lack of grooming

Rough/Ruffled fur

5

Moribund,
Isolated, abnormal

unresponsive or

Activity

Normal

posture

Huddled/inactive

seizuring

Breathing

Normal

Rapid, shallow

Rapid, abdominal

Laboured, blue

Slight

Incoordinated,

Staggering,

incoordination/

walking of toes,

paralysis, lack of

abnormality

reluctant to move

mobility

BC 2+

BC 2

BC 1

Movement

Normal

Condition

BC 3

Skin tents, eyes
Dehydration

Feces

Nil

Normal

Skin less elastic

Skin tents

sunken

Diarrhoea or dry

Uncontrolled

faeces

diarrhoea, Wet tail

growth (e.g. severe

Weight loss

Weight loss >10%

runting)

up to 10% over 24

over 24 hours or

5% over 24 hours

hours

>20% over time

Moist faeces
Markedly reduced

Body Weight
•

Normal

Moribund animals (A lack of responsiveness to manual stimulation, lack of mobility or
inability or failure to eat or drink or a clinical score > 25) will be euthanized.
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Table 2b. Mouse body condition chart
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Figures
Fig. 1. Effect of CR supplementation on the incidence of C. difficile associated diarrhea in
mice
Five to six-week-old C57BL/6 mice were randomly divided into seven treatment groups of 8 mice
each. Mice were fed with irradiated feed supplemented with CR (0%, 0.05%, and 0.1%); the
challenge groups were made susceptible to C. difficile by administering an antibiotic cocktail in
water and an intra-peritoneal injection of clindamycin. Further, challenge and control groups were
infected with 105 CFU/ml of a hypervirulent C. difficile (ATCC 1870) spores or PBS and observed
for clinical signs for ten days. Respective control groups for CR, antibiotics, and their combination
were included for investigating their effect on mouse enteric microflora. The incidence of clinical
signs including diarrhea was recorded from 1DPI to 7DPI. Groups: 1) Negative Control: Mice
treated with no CR, no antibiotics and no C. difficile 2) CR control: Mice fed with 0.1% CR in
feed, 3) Ant Control: Mice administered with antibiotic cocktail in water and an intra-peritoneal
injection of clindamycin, 4) Ant + CR Control: Mice fed with CR (0.1%) supplemented feed and
administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, 5)
Ant+CD: administered with antibiotic cocktail in water and an intra-peritoneal injection of
clindamycin, and infected by C. difficile 6) (Ant + CD + 0.05% CR): Mice fed with CR (0.05%),
administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and
infected with C. difficile ) (Ant + CD + 0.1% CR): Mice fed with CR (0.1%), administered with
antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and infected with C.
difficile.
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Fig. 2. Effect of CR supplementation on the severity of CD associated disease in mice
Five to six-week-old C57BL/6 mice were randomly divided into seven treatment groups of 8 mice
each. Mice were fed with irradiated feed supplemented with CR (0%, 0.05%, and 0.1%); the
challenge groups were made susceptible to C. difficile by administering an antibiotic cocktail in
water and an intra-peritoneal injection of clindamycin. Further, challenge and control groups were
infected with 105 CFU/ml of a hypervirulent C. difficile (ATCC 1870) spores or PBS and observed
for clinical signs for ten days. Respective control groups for CR, antibiotics, and their combination
were included for investigating their effect on mouse enteric microflora. The mice were monitored
for signs of C. difficile infection such as diarrhea, hunched posture and wet tail using a mouse
clinical score sheet. Groups: 1) Negative Control: Mice treated with no CR, no antibiotics and no
C. difficile 2) CR control: Mice fed with 0.1% CR in feed, 3) Ant Control: Mice administered with
antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, 4) Ant + CR Control:
Mice fed with CR (0.1%) supplemented feed and administered with antibiotic cocktail in water
and an intra-peritoneal injection of clindamycin, 5) Ant+CD: administered with antibiotic cocktail
in water and an intra-peritoneal injection of clindamycin, and infected by C. difficile 6) (Ant + CD
+ 0.05% CR): Mice fed with CR (0.05%), administered with antibiotic cocktail in water and an
intra-peritoneal injection of clindamycin, and infected with C. difficile ) (Ant + CD + 0.1% CR):
Mice fed with CR (0.1%), administered with antibiotic cocktail in water and an intra-peritoneal
injection of clindamycin, and infected with C. difficile.
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Fig. 3. Effect of CR supplementation on relative weight loss in C. difficile infected and noninfected mice
Five to six-week-old C57BL/6 mice were randomly divided into seven treatment groups of 8 mice
each. Mice were fed with irradiated feed supplemented with CR (0%, 0.05%, and 0.1%); the
challenge groups were made susceptible to C. difficile by administering an antibiotic cocktail in
water and an intra-peritoneal injection of clindamycin. Further, challenge and control groups were
infected with 105 CFU/ml of a hypervirulent C. difficile (ATCC 1870) spores or PBS and observed
for clinical signs for ten days. Respective control groups for CR, antibiotics, and their combination
were included for investigating their effect on mouse enteric microflora. The body weights of the
animals were recorded daily and the relative percentage weight with respect to the initial weight
prior to the infection was calculated. Groups: 1) Negative Control: Mice treated with no CR, no
antibiotics and no C. difficile 2) CR control: Mice fed with 0.1% CR in feed, 3) Ant Control: Mice
administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, 4)
Ant + CR Control: Mice fed with CR (0.1%) supplemented feed and administered with antibiotic
cocktail in water and an intra-peritoneal injection of clindamycin, 5) Ant+CD: administered with
antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and infected by C.
difficile 6) (Ant + CD + 0.05% CR): Mice fed with CR (0.05%), administered with antibiotic
cocktail in water and an intra-peritoneal injection of clindamycin, and infected with C. difficile )
(Ant + CD + 0.1% CR): Mice fed with CR (0.1%), administered with antibiotic cocktail in water
and an intra-peritoneal injection of clindamycin, and infected with C. difficile.
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Fig. 4. Effect of CR supplementation on the abundance of major gut microbiota (phyla level)
in the antibiotic treated and C. difficile challenged mice
Five to six-week-old C57BL/6 mice were randomly divided into seven treatment groups of 8 mice
each. Mice were fed with irradiated feed supplemented with CR (0%, 0.05%, and 0.1%); the
challenge groups were made susceptible to C. difficile by administering an antibiotic cocktail in
water and an intra-peritoneal injection of clindamycin. Further, challenge and control groups were
infected with 105 CFU/ml of a hypervirulent C. difficile (ATCC 1870) spores or PBS and observed
for clinical signs for ten days. Respective control groups for CR, antibiotics, and their combination
were included for investigating their effect on mouse enteric microflora. The fecal samples were
collected 2 DPI from which DNA was extracted for microbiome analysis using Illumina MiSeq
platform, and the relative abundance of OTUs of major phyla, order, family, and genera was
determined using microbiome analysis. Groups: 1) Negative Control: Mice treated with no CR, no
antibiotics and no C. difficile 2) CR control: Mice fed with 0.1% CR in feed, 3) Ant Control: Mice
administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, 4)
Ant + CR Control: Mice fed with CR (0.1%) supplemented feed and administered with antibiotic
cocktail in water and an intra-peritoneal injection of clindamycin, 5) Ant+CD: administered with
antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and infected by C.
difficile 6) (Ant + CD + 0.05% CR): Mice fed with CR (0.05%), administered with antibiotic
cocktail in water and an intra-peritoneal injection of clindamycin, and infected with C. difficile )
(Ant + CD + 0.1% CR): Mice fed with CR (0.1%), administered with antibiotic cocktail in water
and an intra-peritoneal injection of clindamycin, and infected with C. difficile.
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Fig. 5a & 5b. Effect of CR supplementation on the abundance of Enterobacteriaceae (5a),
Lactobacillaceae (5b) and Lachnospiraceae (5b) in the antibiotic treated and C. difficile
challenged mice
Five to six week-old C57BL/6 mice were randomly divided into 7 treatment groups of 8 mice each.
Mice were fed with irradiated feed supplemented with CR (0%, 0.05%, and 0.1%); the challenge
groups were made susceptible to C. difficile by administering an antibiotic cocktail in water and
an intra-peritoneal injection of clindamycin. Further, challenge and control groups were infected
with 105 CFU/ml of a hypervirulent C. difficile (ATCC 1870) spores or PBS, and observed for
clinical signs for 10 days. Respectiv
e control groups for CR, antibiotics and their combination were included for investigating their
effect on mouse enteric microflora. The fecal samples were collected 2 DPI from which DNA was
extracted for microbiome analysis using Illimina MiSeq platform and the relative abundance of
OTUs at different taxonomic level (Family. Enterobacteriaceae (Fig.5a), Lactobacillaceae and
Lachnospraceae (Fig. 5b) was determined using microbiome analysis. Groups: 1) Negative
Control: Mice treated with no CR, no antibiotics and no C. difficile 2) CR control: Mice fed with
0.1% CR in feed, 3) Ant Control: Mice administered with antibiotic cocktail in water and an intraperitoneal injection of clindamycin, 4) Ant + CR Control: Mice fed with CR (0.1%) supplemented
feed and administered with antibiotic cocktail in water and an intra-peritoneal injection of
clindamycin, 5) Ant+CD: administered with antibiotic cocktail in water and an intra-peritoneal
injection of clindamycin, and infected by C. difficile 6) (Ant + CD + 0.05% CR): Mice fed with
CR (0.05%), administered with antibiotic cocktail in water and an intra-peritoneal injection of
clindamycin, and infected with C. difficile 7) (Ant + CD + 0.1% CR): Mice fed with CR (0.1%),
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administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and
infected with C. difficile. (Treatments significantly differed from the negative control (p<0.05)
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Fig. 5a
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Fig. 5b
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Fig. 6. Effect of CR supplementation on the diversity of gut microbiota of antibiotic treated
and C. difficile challenged mice
Five to six week-old C57BL/6 mice were randomly divided into 7 treatment groups of 8 mice each.
Mice were fed with irradiated feed supplemented with CR (0%, 0.05%, and 0.1%); the challenge
groups were made susceptible to C. difficile by administering an antibiotic cocktail in water and
an intra-peritoneal injection of clindamycin. Further, challenge and control groups were infected
with 105 CFU/ml of a hypervirulent C. difficile (ATCC 1870) spores or PBS, and observed for
clinical signs for 10 days. Respective control groups for CR, antibiotics and their combination
were included for investigating their effect on mouse enteric microflora. The fecal samples were
collected 2 DPI from which DNA was extracted for microbiome analysis using Illumina MiSeq
platform, and Alpha diversity was calculated by using inverse Simpson to measure the richness
and evenness of the OTUs. Groups: 1) Negative Control: Mice treated with no CR, no antibiotics
and no C. difficile 2) CR control: Mice fed with 0.1% CR in feed, 3) Ant Control: Mice
administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, 4)
Ant + CR Control: Mice fed with CR (0.1%) supplemented feed and administered with antibiotic
cocktail in water and an intra-peritoneal injection of clindamycin, 5) Ant+CD: administered with
antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and infected by C.
difficile 6) (Ant + CD + 0.05% CR): Mice fed with CR (0.05%), administered with antibiotic
cocktail in water and an intra-peritoneal injection of clindamycin, and infected with C. difficile 7)
(Ant + CD + 0.1% CR): Mice fed with CR (0.1%), administered with antibiotic cocktail in water
and an intra-peritoneal injection of clindamycin, and infected with C. difficile.
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Fig. 7. Effect of CR supplementation on the diversity of gut microbiota of antibiotic treated
and C. difficile challenged mice
Five to six week-old C57BL/6 mice were randomly divided into 7 treatment groups of 8 mice each.
Mice were fed with irradiated feed supplemented with CR (0%, 0.05%, and 0.1%); the challenge
groups were made susceptible to C. difficile by administering an antibiotic cocktail in water and
an intra-peritoneal injection of clindamycin. Further, challenge and control groups were infected
with 105 CFU/ml of a hypervirulent C. difficile (ATCC 1870) spores or PBS, and observed for
clinical signs for 10 days. Respective control groups for CR, antibiotics and their combination
were included for investigating their effect on mouse enteric microflora. The fecal samples were
collected 2 DPI from which DNA was extracted for microbiome analysis using Illumina MiSeq
platform. Relationships between treatment groups based on the abundance of species present in
each sample were plotted. NMS ordinations were run in R (v 3.3.0) using metaMDS in the vegan
(v 2.3-5) package after calculating the stress scree plots to determine the number of axes required
to achieve stress below 0.2, plotted using ggplot2 (v 2.1.0). Groups: 1) Negative Control: Mice
treated with no CR, no antibiotics and no C. difficile 2) CR control: Mice fed with 0.1% CR in
feed, 3) Ant Control: Mice administered with antibiotic cocktail in water and an intra-peritoneal
injection of clindamycin, 4) Ant + CR Control: Mice fed with CR (0.1%) supplemented feed and
administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, 5)
Ant+CD: administered with antibiotic cocktail in water and an intra-peritoneal injection of
clindamycin, and infected by C. difficile 6) (Ant + CD + 0.05% CR): Mice fed with CR (0.05%),
administered with antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and
infected with C. difficile 7) (Ant + CD + 0.1% CR): Mice fed with CR (0.1%), administered with
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antibiotic cocktail in water and an intra-peritoneal injection of clindamycin, and infected with C.
difficile.
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Chapter VII
Summary
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Clostridium difficile is a nosocomial pathogen that causes a toxin-mediated enteric disease
in human. More than 300,000 cases of C. difficile-associated disease (CDAD) are reported
annually in the United States, resulting in more than US$3 billion as healthcare costs. According
to US Department of Health and Human Services, the New England region, including Connecticut
reported the highest rate of C. difficile associated hospitalizations in recent years. C. difficile
mostly affects long-term hospital inpatients and the elderly undergoing prolonged antibiotic
therapy. Prolonged antibiotic therapy results in gut dysbiosis, leading to the germination of C.
difficile spores and pathogen colonization in the intestine with subsequent production of toxins. C.
difficile, TcdA, and TcdB, cause severe inflammatory response with the release of cytokines and
leukotrienes, leading to pseudomembrane formation in the intestine and watery diarrhea.
The incidence and severity of the disease associated with C. difficile have increased in the
US with the emergence of hypervirulent strains and community associated outbreaks. The
detection of genotypically similar and identical C. difficile strains implicated in human infections
from foods and food animals indicate the potential role of food as a source of community
associated C. difficile disease. In this study, we investigated the prevalence of C. difficile spores in
retail meat sold in Connecticut. One hundred samples each of ground beef, pork and chicken
obtained from geographically distant grocery stores in Connecticut were tested for C. difficile.
Positive isolates were characterized by ribotyping, antibiotic susceptibility, toxin production and
whole genome sequencing. Of the 300 meat samples, only two pork samples tested positive for
C. difficile indicating a very low prevalence of C. difficile in meat. The isolates were non-toxigenic,
but found to have an array of antibiotic resistance genes and mobile elements, which can
potentially contribute to the generation of multi-drug resistant toxigenic strains.
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Although exposure to broad-spectrum antibiotics predisposes patients to C. difficile
associated disease (CDAD) by disrupting the normal gut flora, antibiotics are still the primary line
of treatment against the disease. In addition, the emergence of antibiotic resistance in hypervirulent
strains of C. difficile is increasingly reported worldwide, which raises concerns on the success of
antibiotic treatment. Since C. difficile toxins are the major virulence factors responsible for the
pathogenesis of CDAD, reducing C. difficile toxin production could significantly minimize its
pathogenicity and improve disease outcome in humans. Therefore, the second objective of this
research work investigated the efficacy of two, food-grade, plant-derived compounds, namely
trans-cinnamaldehyde (TC) and carvacrol (CR) in reducing C. difficile toxin production and
cytotoxicity in vitro. The effect of CR and TC on toxin production genes in a codY mutant and
wild type C. difficile was also investigated. Carvacrol and TC substantially reduced C. difficile
toxin production and cytotoxicity on Vero cells. The plant compounds also significantly downregulated toxin production genes. Carvacrol and TC did not inhibit toxin production in the codY
mutant of C. difficile, suggesting a potential codY-mediated anti-toxigenic mechanism of the plant
compounds. In addition, this study revealed that the antitoxigenic concentrations of CR and TC
did not inhibit the growth of beneficial gut bacteria. The results from this study suggest the
potential use of TC and CR to attenuate C. difficile virulence
Although toxins are the major virulence factors responsible for the pathogenesis of C.
difficile infection, spore formation, germination and outgrowth in C. difficile are critical for
transmission and relapse of the disease. Spore production is a complex process in C. difficile,
regulated by a set of genes, including spo0A, which is the master regulator of sporulation initiation
along with associated kinases and different sigma factors such as sigH. Spores are shed in the
feces, which contaminate hospitals and healthcare facilities causing infection through faeco-oral
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route or recurrence of C. difficile associated disease in patients following germination of spores.
Therapeutic agents that are capable of reducing C. difficile spore production could significantly
minimize the transmission and relapse of C. difficile infections. Therefore, our third objective
investigated the ability of carvacrol to reduce C. difficile spore production, germination and spore
outgrowth. Moreover, the effect of CR on C. difficile sporulation genes was investigated using
real-time qPCR. Carvacrol significantly reduced sporulation in C. difficile and down-regulated
critical genes involved in spore production. Carvacrol did not inhibit C. difficile spore germination,
however, it completely inhibited spore outgrowth. The results from this study suggest that CR
could potentially be used to control spread and relapse of difficile by reducing spore production
and outgrowth.
To validate the results from the second and third objectives of this study, a mouse
experiment was conducted to investigate the effect of CR supplementation on C. difficile infection
in vivo. Carvacrol supplementation significantly reduced the incidence of diarrhea and improved
the clinical and diarrhea scores in mice (p<0.05). Microbiome analysis revealed a significant
increase in Proteobacteria and reduction in protective bacterial flora in antibiotic-treated and C.
difficile -infected mice compared to control (p<0.05). However, CR supplementation positively
altered the microbiome composition, as revealed by an increased abundance of beneficial bacteria,
including Firmicutes, and significantly reduced the proportion of detrimental flora such as
Proteobacteria, without significantly affecting the gut microbiome diversity. Our results suggest
that CR could potentially be used to control gut dysbiosis and reduce C. difficile infection.
To conclude, the results of this Ph.D. research workindicate the therapeutic potential of CR
and TC against C. difficile infection in humans. In addition, this study confirmed that C. difficile
occurs at very low levels in retail meat sold in Connecticut.
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